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Every 25 minutes in the United States, a newborn is born experiencing neonatal abstinence 
syndrome. Neonatal abstinence syndrome is a withdrawal syndrome cause by exposure to 
medications or drugs in utero that leads to symptoms of withdrawal leading to extensive, high 
cost hospital stays. Little is known about the neurodevelopmental effects of neonatal abstinence 
syndrome beyond the age of five. The purpose of this study was to 1) describe the 
neurodevelopmental health of children with NAS at 10 years of age, 2) examine the relationship 
between NAS and neurodevelopment (i.e. abnormal behavioral, cognitive, and motor 
development) at the ages of 1, 5, and 10 years, and 3) examine the longitudinal effect of NAS on 
neurodevelopment (i.e., learning disorders and language delays) from birth to 10 years. This 
work extended that knowledge by analyzing data on children who presented, during the newborn 
period, with the clinical signs and symptoms of NAS to examine the effect of NAS on 
neurodevelopmental outcomes through the age of ten. This work identified that at the age of ten 
(n=234) children with a history of NAS experienced learning disorders, language delays, 
abnormal behavioral development, and abnormal cognitive development. At the age of ten 
(N=727), NAS significantly predicted abnormal behavioral development in children with a 
history of NAS (p<.01). Findings did not significantly predict abnormal cognitive or motor 
development. Further, over the first ten years of life children (N=727) with a history of NAS had 
a significantly different pattern of language delay than those without NAS (p<.01). There was no 
significant difference in patterns of learning disorders. Implications for practice, research, and 
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NAS A withdrawal syndrome experienced by newborns exposed to 
opioids in utero (Bailey, 2015). 
Children A person under the age of 18 (HHS, 2016) 
Neurodevelopment  The growth and development of the brain and nervous system 
(Spear, 2013) 
Neurodevelopmental disorders Neurodevelopmental disorders are those that affect physical 
movement, learning, language, and behavior emerging in 
childhood and affecting behaviors of everyday functioning. 
They include intellectual disabilities, communication disorders, 
autism spectrum disorder, learning disabilities, specific learning 
disorder, and attention-deficit/hyperactivity disorder (ADHD) 
(APA, 2013). 
Opioids Opioids are a class of drugs naturally found in the opium poppy 
plant, including heroin, oxycodone, codeine, methadone, and 
buprenorphine (NIDA, 2018b).  
Hyperactive moro reflex Prolonged infantile reflex exhibited with the sudden loss of 
support characterized by the arms extended for greater than 3 
seconds with or without tremors (Meyer and Phillips, 2015).  
Hypertonicity Difficulty or inability to straighten arms or legs when an infant 
is lying supine (Meyer and Phillips, 2015).  
Excoriation Red or broken skin from excessive rubbing (Meyer and Phillips, 
2015).  
Low birth weight A birth weight less than 2500 grams (Cutland et al., 2017).  
ADHD A brain-based neurodevelopmental disorder characterized by 
developmentally inappropriate levels of inattention and/or 
hyperactivity and impulsivity (McGough, 2014).  
Learning disability A neurodevelopmental disorder that involves ongoing problems 
learning key academic skills, including reading, writing and 
math (APA, 2013). 
Intellectual Disability A neurodevelopmental disorder begins in childhood and 
includes intellectual difficulties, as well as difficulties in 
conceptual, social, and practical areas of living.  
Developmental Disability A severe, long term disability that may affect cognitive ability, 
physical functioning, or both occurring before the age of 22 and 
likely to be life-long (NIH, 2018).  











In more than a decade, the United States (US) has experienced a 300% increase in 
diagnoses of Neonatal Abstinence Syndrome (NAS) (Ko, Patrick, Patel, Lind & Barfield, 2016). 
This equates to one newborn being diagnosed with NAS every 25 minutes (Patrick, Davis, 
Lehmann, & Cooper, 2015). NAS, a newborn withdrawal syndrome, is a national health 
epidemic (Bauer & Li, 2013). In 2014, nearly 32,000 newborns were diagnosed with NAS 
(Winkelman, Villapiano, Kozhimannil, Davis, & Patrick, 2018). Despite the staggering numbers 
of infants born with NAS, little is known about the long-term effects on child health, specifically 
the effects on neurodevelopment. Understanding how a history of NAS effects infants and 
children over time will guide the development of screening tools, early interventions, and policy 
to ensure access to needed health care.  
Maternal substance use during pregnancy causes documented negative effects on 
newborns and is the precursor to NAS, leading to low birth weight, neurological excitability, 
gastrointestinal distress, and autonomic reactivity (Lee, 2015; Maguire et al., 2016; McQueen & 
Murphy-Oikonen, 2016). NAS is most commonly associated with the use of opioids, however 
NAS may occur with exposure to methamphetamines, anti-depressants, and benzodiazepines, by 
the mother during pregnancy leading to dependency in the infant (Hudak et al., 2012; Jones, et 
al., 2010; Jansson et al., 2017; Klinger et al., 2011; Lee, 2015; Raffaeli et al., 2017). Dependence 
occurs when the infant functions normally only during exposure to the drug, thus they present 
with physical disturbances of withdrawal when the drug is removed (National Institute on Drug 
Abuse, 2018).  
The onset of symptoms is associated with the half-life of elimination of the drug (Hudak 
et al., 2012). NAS attributed to heroin withdrawal generally presents around 24 hours post-




Jones, et al., 2010; Lee, 2015). Buprenorphine has an onset of withdrawal around 40 hours after 
delivery (Hudak & Tan, 2012; Jones et al., 2010; Lee, 2015). The severity of the symptoms 
varies based on the type of drug taken (Hudak et al., 2021). NAS due to methadone exposure is 
associated with higher treatment doses of morphine to manage withdrawal symptoms, longer 
hospital stays, and longer duration of treatment versus buprenorphine or heroin (Jones et al., 
2010). Symptoms of NAS include, but are not limited to, mottled skin, inconsolable and high-
pitched crying, hypertonicity, hyperactive moro reflex, difficulty eating, poor weight gain, and 
seizures  (Lee, 2015; McQueen & Murphy-Oikonen, 2016). Diagnosis of NAS usually occurs by 
the fifth day of life  (Maguire, et al., 2016; Lee, 2015) lasting up to six months of age (Desmond 
& Wilson, 1975). 
The negative impact of NAS on health care utilization and costs is substantial and 
projected to increase. NAS-related admissions to neonatal intensive care units (NICUs) increased 
from 7:1000 to 27:1000 from 2004 to 2013 (Tolia et al., 2015). In states with the highest 
incidence of NAS, such as Tennessee, at least 92% of children born with NAS were on Medicaid 
and 15% had social service involvement with out-of-home placement (TDHCFA, 2017). In 
2015, the average cost per NAS newborn, during the initial hospitalization (at birth), was 
$44,314, approximately 10 times higher than the costs for a normal birth-weight, non-NAS birth 
(TDHCFA, 2017). Additionally, there is a significant association between diagnosis of NAS and 
hospital readmission (Patrick, Burke, Biel, Auger, Goyal, & Cooper, 2015). The cost of care for 
newborns with NAS increased from $732 million in 2009 to $1.5 billion in 2012 (Patrick, Davis, 
et al., 2015). The estimated lifetime costs associated with NAS are expected to exceed $100,000 
per year per child (O’Brien & Phillips, 2011). In some states, such as Massachusetts, it is 




services for children with NAS (Franca, Mustafa, & McManus, 2016). Thus, there is an 
increased cost of care associated with newborns diagnosed with NAS. Therefore, a better 
understanding of the long-term heath effects may capture a better understanding of the long-term 
associated costs.   
Early evidence suggests exposure to opioids in utero leads to increased risk for adverse 
neurodevelopmental health outcomes in early childhood; however, there is a lack of empirical 
evidence on the effects of a history of NAS as children age (Hudak et al., 2012; Bunikowski, 
Grimmer, Heiser, Metze, Schafer, & Obladen, 1998; Hunt, et al., 2008; McGlone & Mactier, 
2015). Neurodevelopmental health outcomes include disorders that affect physical movement, 
learning, language, and behavior. Neurodevelopmental disorders emerge in childhood and affect 
behaviors of everyday functioning, ranging from intellectual disabilities, communication 
disorders, autism spectrum disorder, learning disabilities, specific learning disorder, and 
attention-deficit/hyperactivity disorder (ADHD) (American Psychiatric Association [APA], 
2013). 
Maternal opioid use during pregnancy has a direct impact on development (McGlone & 
Mactier, 2015; Sirnes et al., 2017) by decreasing fetal/newborn brain volume (Sirnes et al., 
2017), reducing newborn motor function (Bunikowski et al., 1998), and increasing the risk of 
adverse intellectual and developmental effects among exposed newborns (Hunt et al., 2008). 
Research conducted before the age of five suggests that children with a history of opioid 
exposure in utero have poorer neurodevelopmental health than those who were not exposed 
(Bunikowski et al., 1998; Hudak, et al., 2012; Hunt et al., 2008; McGlone & Mactier, 2015; 
Wang & Han, 2009). Thus, the impact of NAS on the central nervous system of the developing 




A study of three-year old children found those exposed to opioids in utero showed a 
significant decrease in developmental outcomes, such as cognition and verbal communication as 
measured by the Bayley Scales of Infant Development-Mental Development Index (Bayley, 
1993), along with significantly lower scores in communication and behavior as measured with 
the Vineland Social Maturity Scale (Sparrow, 2011) versus the control group at both 18 months 
and 3 years of age (Hunt et al., 2008). Children exposed to opioids in utero have a significant 
positive association with a diagnosis of ADHD (Sirnes et al., 2017). Magnetic resonance imaging 
of newborns with a history of in utero opioid exposure showed decreased brain volumes (basal 
ganglia and cerebellar white matter) in those exposed compared with those without exposure, 
after controlling for a diagnosis of ADHD and birth weight (Sirnes et al., 2017). Thus, exposure 
to opioids in utero may negatively influence neurodevelopment in young childhood, yet this is 
only part of the story as information on the long-term effect of NAS is missing.  
In summary, the current literature provides compelling evidence that maternal opioid 
exposure and the health conditions associated with NAS influence neurodevelopment. However, 
there is still a significant gap in our understanding of the direct role of NAS on 
neurodevelopment, given few studies were identified that examined this relationship. In addition, 
minimal studies have explored this relationship as a child matures and develops neurologically. 
The purpose of the proposed study was to address these gaps and generate evidence about the 
effect of NAS on neurodevelopment between the ages of birth and 10 years, with additional 
analysis at specific ages of 1, 5, and 10 years.  
Several researchers have shown a relationship between NAS and adverse 
neurodevelopmental outcomes in early childhood, however, there has been lack of research as 




language and hearing, hand/eye coordination, and developmental performance as measured with 
the Griffith’s Developmental Quotient Scale (DQ) (McGlone & Mactier, 2015). Children, ages 
three to eight, with a history of NAS had more evaluation for, diagnosis of, and accommodations 
for educational disabilities than children without a history of NAS (Fill, Miller, Wilkinson, 
Warren, Dunn, Schaffner, & Jones, 2018). In addition, children with a history of NAS had more 
behavioral, emotional, and developmental diagnoses at 24 months of age than those who 
experienced in utero opioid exposure but without a diagnosis of NAS (Hall, McAllister, & 
Wexelblatt, 2018). Using the research performed during early childhood (i.e. birth to 8 years 
[World Health Organization, 2016]), it is hypothesized that NAS would have a negative effect on 
children throughout childhood (1 – 10 years).  
AIM 1: To describe the neurodevelopmental health of children with NAS at 10 years of 
age.  
 AIM 2: To examine the relationship between NAS and neurodevelopment (i.e., abnormal 
behavioral, cognitive, and motor development) at the ages of 1, 5, and 10 years. Based on 
previous research (Hunt et al., 2008; Hudak & Tan, 2012; McGlone & Mactier, 2015; Sirnes, 
2017; Fill et al. 2018) and using the SEM as a guide, the following hypotheses are proposed:  
• Hypothesis 2: NAS will be associated with abnormal behavioral, cognitive, and motor 
development at the ages of 1, 5, and 10 years, while controlling for interpersonal, 
intrapersonal, community, organizational, and public policy factors. 
Hypothesis 2A: NAS will be associated with abnormal behavioral, cognitive, and motor 
development at 1 year. 
Hypothesis 2B: NAS will be associated with abnormal behavioral, cognitive, and motor 




Hypothesis 2C: NAS will be associated with abnormal behavioral, cognitive, and motor 
development at 10 years. 
AIM 3: To examine the longitudinal effect of NAS on neurodevelopment (i.e., learning 
disorders and language delays) from birth to 10 years. Based on the literature relating NAS to 
adverse neurodevelopmental findings (Hall et al., 2018; Fill et al. 2018), the following 
hypothesis is proposed: 
• Hypothesis 3: NAS will be associated with learning and language disorders over 10 
years.  
Significance of the Study 
A review of the literature indicates that this study was the first to examine the long-term 
effect of NAS on neurodevelopmental health of children through the age of 10 years, while 
controlling for child, family, community, and societal characteristics. This study examined the 
long-term impact on children over a 10 year time span, as well as examining the age-specific 
relationship between NAS and neurodevelopmental outcomes at 1, 5, and 10 years. Previous 
studies have addressed the effects of opioid exposure or NAS on developmental outcomes 
through the age of four. In addition, prior research has not included fully-specified models that 
include potential confounding variables such as child, family, community, and societal 
characteristics.  
 Understanding the influence of NAS on neurodevelopment is important clinically for 
nurses. Evidence from this study may inform clinicians about the role of NAS in 
neurodevelopment and provide insight into potential clinical practices, such as NAS screening; a 
key component of early intervention. Most importantly, the findings may influence clinical care 




for children with a history NAS and their families. Researchers can use the findings to allocate 
limited resources either to develop age-specific interventions to lessen the effects of disability or 
to ensure availability of adequate resources for the population of children with a history of NAS. 
In addition, research on the long-term effects of NAS is policy relevant. As policies are being 
enacted at the state and federal levels, it is critical to understand the potential effects of NAS on 
long-term neurodevelopmental health outcomes, both to assist in developing age-specific 
interventions, as well as to inform policy to support the affected children. The lack of evidence 
on the long-term effect of NAS impairs the ability of the state and federal government to 
understand the societal cost of NAS across the lifespan. Thus, this study can provide insight of 
the potential outcomes and expected expenses over the course of the child’s life.  
Theoretical Framework 
The Social-Ecological Model (SEM) was used to conceptualize the relationship between 
NAS and neurodevelopmental health outcomes (McLeroy, Bibeau, Streckler, & Glanz, 1988). 
The main assumption of the SEM is intrapersonal, interpersonal, organizational, community, and 
public policy factors influence health  (Figure 1). Intrapersonal factors include biological make-
up, knowledge, attitudes, and behaviors (McLeroy et al., 1988). Interpersonal factors are 
relationships with family, friends, and peer groups that influence an individual’s health. 
Organizational factors are rules, regulations, and policies that may promote or hinder health. 
Community factors are neighborhoods in which an individual belongs. The public policy factors 
include local, state, and national policies and laws that may directly or indirectly affect health. 
For this study, I focused on the intrapersonal factors of NAS, which are factors that occur within 




socioeconomic status), organizational (i.e., CPS referral), community (i.e., region and type of 
housing), and public policy (i.e., insurance status) factors as covariate variables. 
Summary 
This dissertation is divided into five chapters, or manuscripts, and a conclusion section. 
Chapter 1 presents a literature review of the current state of knowledge of the long-term effects 
of NAS on neurodevelopmental health outcomes and includes a discussion of gaps in the 
literature and implications. Chapters 2, 3, and 4 report the findings of the three aims of the 
dissertation study describing the theoretical model and methodology of each study, including 
research design, sampling, measures, data sources, data analysis, and analytical issues. Chapter 5 




Figure 1. Conceptual Model of Neurodevelopmental Health. Note. Adapted from “An Ecological 
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Abstract 
Despite the alarming increase in the numbers of infants born with neonatal abstinence 
syndrome (NAS), little is known about the effect on the children past the age of four. Clinical 
findings associated with NAS are found in the literature to have a negative effect on 
neurodevelopmental health outcomes. The purpose of this review is to examine the current 
evidence regarding NAS and neurodevelopmental outcomes, identify gaps in the literature, and 
discuss the possible association between NAS symptoms and neurodevelopmental disorders. A 
comprehensive literature review of quantitative research and review articles identified human 
and animal studies to clarify the current knowledge on the long-term effects of opioid exposure 
and NAS on neurodevelopmental outcomes. The analysis found that infants exposed to opioids 
in utero are at risk for poorer neurodevelopmental outcomes in early childhood; however, there 
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Neonatal abstinence syndrome (NAS), a withdrawal syndrome that occurs in infants 
exposed to opioids in utero, is a national health epidemic (Bauer & Li, 2013). Maternal use of 
opioids during pregnancy causes documented negative effects on neonates and is the precursor to 
NAS, which leads to low birth weight, neurological excitability, gastrointestinal distress, and 
autonomic reactivity (Lee, 2015; Maguire et al., 2016; McQueen & Murphy-Oikonen, 2016). 
The United States experienced a 380% increase in diagnoses of NAS from 1999 to 2013, leading 
to an estimated 28,000 infants diagnosed in 2013 alone (Ko et al., 2016; Patrick et al., 2015). 
NAS-related admissions to neonatal intensive care units (NICUs) increased from 7:1000 to 
27:1000 from 2004 to 2013 (Tolia et al., 2015). Additionally, the cost of care for infants with 
NAS increased from $732 million in 2009 to $1.5 billion in 2012 (Patrick et al., 2015).  
 NAS occurs in infants following the use of opioids by the mother during pregnancy 
(Hudak et al., 2012; Jones, et al., 2010; Lee, 2015). Opioids, both legal and illegal, including 
heroin, oxycodone, codeine, methadone, and buprenorphine, cross the placenta, leading to 
dependency in the infant (Lee, 2015). Dependence occurs when the infant functions normally 
only during exposure to the drug, thus they present with physical disturbances of withdrawal 
when the drug is removed (NIDA, 2007). Symptoms of NAS are in Table 1.1 and include, but 
are not limited to, mottled skin, inconsolable and high-pitched crying, hypertonicity, 
hyperreactive reflexes, difficulty eating, poor weight gain, and seizures  (Lee, 2015; McQueen & 







Table 1.1.  
Symptoms Associated with NAS 
 Neurological Excitability  Gastrointestinal Distress Autonomic Reactivity 
Exaggerated moro reflex Dehydration Increased sweating 
Frequent yawning Diarrhea Mottled skin 
High-pitched crying Excoriation Nasal stuffiness 
Hyperactive reflexes Poor feeding  Temperature instability 
Hypertonicity Poor suck reflex 
 Increased respiratory rate Poor weight gain 
 Irritability Vomiting 
 Seizures 
  Sneezing 
  Tremors 
  Trouble sleeping   
Note. Adapted from “Neonatal abstinence syndrome” by K. Lee; “Neonatal abstinence syndrome” by J. 
McQueen & K. Murphy-Oikonen; and “Long-term outcomes of infants with neonatal abstinence 












Diagnosis of NAS usually occurs by the fifth day of life with onset of symptoms 
dependent on the type of drug taken by the mother (Maguire, et al., 2016; Lee, 2015) and lasting 
up to six months of age (Desmond & Wilson, 1975). Although the clinical findings of NAS in 
the period following birth have been well documented, minimal research is available regarding 
the effects of NAS on neurodevelopmental health, particularly the association between NAS and 
incidences of neurodevelopmental disorders during childhood. Neurodevelopmental disorders 
emerge in childhood and affect behaviors of everyday functioning, ranging from intellectual 
disabilities, communication disorders, autism spectrum disorder, learning disabilities, specific 
learning disorder, and attention-deficit/hyperactivity disorder (ADHD) (American Psychiatric 
Association, 2013). Clinical findings associated with NAS can be linked to decreased 
neurodevelopmental health, thus a review of current empirical findings is necessary to determine 
the current state of knowledge. Understanding the current state of the science can assist with 
development of clinical interventions, such as early NAS screening, targeted to the appropriate 
age group and assist policy makers and advocates understand how the opioid epidemic affects 
the most vulnerable population in our society. The purpose of this review is to examine the 
current evidence regarding NAS and neurodevelopmental outcomes, identify gaps in the 
literature, and discuss the possible association between NAS symptoms and neurodevelopmental 
disorders.  
Methods  
A comprehensive literature review identified articles related to the topics of NAS and 
neurodevelopmental outcomes through a search of PubMed, PsychINFO, and CINAHL with 
multiple combinations of keywords including “Neonatal Abstinence Syndrome,” OR “NAS,” 




“developmental disabilities,” OR “intellectual disabilities”, OR “neurodevelopment.” The search 
was limited to peer-reviewed journal articles and literature review articles with no limit on 
publication dates. Initial literature searches identified 222 articles. After reviewing titles for 
duplicate and non-related content, abstracts for 96 articles were reviewed further. Twenty-five 
articles were chosen for inclusion and extensive critique (Figure 1.1). A review matrix was 
organized for synthesis of the findings. The review of the literature identified human and animal 
studies to clarify the current knowledge on the long-term effects of opioid exposure and NAS on 
neurodevelopmental outcomes. 
Results  
Infants exposed to opioids in utero are at risk for poorer neurodevelopmental outcomes in 
early childhood; however, there is a lack of empirical evidence on the effect of NAS as children 
age (Bunikowski et al., 1998; Hudak, et al., 2012; Hunt et al., 2008; McGlone & Mactier, 2015; 
Wang & Han, 2009). Current research focuses primarily on children under the age of five, often 
without a diagnosis of NAS, but with maternal exposure to opioids in utero. Research performed 
during early childhood indicates that children exposed to opioids during pregnancy have poorer 
neurodevelopmental outcomes than those who were not exposed. Neurodevelopmental outcomes 
are measured with specific indicators of health and development using standardized scales tested 
for reliability and validity (CDC, 2014). Findings related to neurodevelopmental outcomes vary 
in the available literature. 
In the detailed review and synthesis of 25 articles, four themes emerged regarding the 
association between NAS and neurodevelopmental outcomes: (a) developmental outcomes, (b) 
intellectual outcomes, (c) behavioral outcomes, and (d) neurophysiological outcomes. We 





Figure 1.1. Inclusion and Exclusion Criteria  
 
Developmental Outcomes  
Infants born to mothers using prescribed methadone during pregnancy scored 
significantly lower on the Griffith’s Developmental Quotient (DQ) scale, even when taking into 
account smoking and alcohol consumption during pregnancy (McGlone & Mactier, 2015). The 
Griffith’s DQ scale measures the development of infants and young children from birth to 2 
years of age measuring locomotor skills, personal-social measures, hearing and language, eye 
and hand coordination, and performance (Griffiths, 1996). Bunikowski and colleagues (1998) 
also found that children at one year of age exposed to opioids in utero showed a significant 
decrease on the Griffith’s DQ scale by having poorer ability to move from one place to another 
and worse intellectual performance compared with children not exposed. Additionally, a study of 
three-year old children found those exposed to opioids in utero showed a significant decrease in 
developmental outcomes on the Bayley Scales of Infant Development-Mental Development 




the control group at both 18 months and 3 years of age (Hunt et al., 2008). Infants exposed to 
opioids in utero who were raised in their biological home scored lower, though not significantly, 
on the MDI than those children raised in adopted homes and the control group, while those 
exposed and living in a lower socioeconomic status home showed significantly lower 
developmental test scores (Ornoy, 2003).  
Intellectual Outcomes  
Exposure to opioids in utero is associated with significant decreases on intellectual tests. 
At one year of age, children exposed to opioids during pregnancy demonstrated a significant 
increase in mild retardation and neurological deviations versus unexposed children (Bunikowski, 
et al., 1998). In a longitudinal, case-control study of methadone-exposed versus non-exposed 
children measured at 18 months and 3 years of age, children exposed to methadone in utero were 
significantly more likely to score lower on intelligence scales, including the Stanford-Binet 
Intelligence Scale, Reynell Expressive Language Scale, and the Reynell Verbal Comprehension 
Scale at both time points. Among seventh graders with a previous diagnosis of NAS, 37.7% did 
not meet the National Minimum Standard on one or more sections of national standardized tests 
compared with 18.4% who did not meet the national standard in the control group (Oei et al., 
2017). Additionally, in 7th grade, children with NAS scored lower than children in 5th grade on 
standardized testing (Oei, et al., 2017).  
Behavioral Outcomes 
Prenatal exposure to opioids is associated with lower scores on behavioral scales, as well 
as a significant increase in the diagnosis of ADHD. Children between the ages of 10 and 14 years 
with exposure to opioids in utero are significantly more likely to have a diagnosis of ADHD 




significantly associated with the use of opioids during pregnancy, despite controlling for living in 
a biological home versus living in an adoptive home (Ornoy, 2003).  
Neurophysiological Outcomes 
 Research has varied regarding the association of infant head circumference (HC) with in 
utero opioid exposure or NAS. Exposed two-year-olds followed in a prospective, cohort study 
had significantly smaller HC than the control group (Hans, 1989). Additionally, studies by Hunt 
and colleagues (2008) and Moe (2002) identified significantly smaller HC for exposed infants. 
Similarly, a retrospective study of birth outcomes found a significant decrease in HC in infants 
exposed to methadone in utero versus naltrexone, buprenorphine, and the control group (Kelty & 
Hulse, 2017). Furthermore, findings of significantly smaller HC differences were identified in 
infants exposed to high-dose methadone management versus low-dose methadone and 
buprenorphine exposure (Bier et al., 2015). However, additional studies have provided 
inconsistent findings, with no significant difference in HC in exposed infants (Kaltenbach et al., 
2017; McGlone & Mactier, 2015; Sirnes, 2017; Wiegand et al. 2015).   
Sirnes (2017) completed a study of magnetic resonance imaging (MRI) in children ages 
10–14 years with previous in utero opioid exposure and found decreased brain volumes (basal 
ganglia and cerebellar white matter) in those exposed compared with those without in utero 
opioid exposure, after controlling for a diagnosis of ADHD and birth weight. Additionally, a 
study of in utero heroin exposure in rats measured the effects of heroin on the hippocampus, 
which plays a role in learning and memory (Wang & Han, 2009). Wang and Han (2009) showed 
that in utero heroin exposure enhances apoptosis, or cell death, of hippocampal neurons, leading 





 The increase in the number of infants diagnosed with NAS raises concerns about 
associated long-term health outcomes, specifically neurodevelopment. There are currently no 
clear empirical findings of the long-term effects of NAS on neurodevelopmental outcomes. The 
clinical findings of NAS during the newborn period may explain the potential long-term 
findings, though not all withdrawal symptoms have a relationship with potential negative long-
term effects. Although the long-term impacts specific to NAS are not yet fully understood, there 
is ample evidence of the impact of clinical findings associated with NAS on neurodevelopmental 
outcomes, including low birth weight (LBW), poor feeding, poor weight gain, and seizures. We 
provide a description of such outcomes in the following paragraphs. 
Low Birth Weight 
 Low birth weight (LBW), or a birth weight of less than 2500 grams, is associated with 
decreased academic performance and diagnosed neurodevelopmental disorders. A study of 
children ages 6–15 years born at less than 2500 grams showed a significant likelihood to repeat a 
grade and attend special education classes compared with children born at normal birth weight 
(Cormana & Chaikind, 1998). Boardman and colleagues (2002) found significantly lower scores 
on the Peabody individual achievement test in mathematics and reading recognition (PIAT-M, 
PIAT-RR) for LBW infants, while controlling for social risk factors (i.e., race/ethnicity, gender, 
maternal level of education, poverty status, maternal marital status). In addition, a secondary 
analysis of data from the National Health Interview Survey Sample Child Core from 1997–2005 
found a correlation between LBW and diagnoses of one developmental delay (DD), 3+ DD, 




(Boule et al., 2011). Thus, there is an association between LBW infants and neurodevelopmental 
disorders.  
Poor Feeding and Weight Gain 
Clinical findings of NAS include poor feeding and poor weight gain, which can lead to 
malnutrition (Lee, 2015). Poor feeding and poor weight gain in NAS infants is related to an 
uncoordinated suck and swallow pattern leading to an inability to effectively feed from a bottle 
or nipple (Finnegan et al., 1975). Malnutrition and failure to thrive (FTT) occur when the child 
ranks below the fifth percentile on a standard growth chart (Corbett & Drewett, 2004). A 
systematic review of the literature indicated that infants with FTT demonstrate adverse 
intellectual outcomes as evidenced by lower intelligent quotient (IQ) scores and lower scores on 
the McCarthy Scales and Bayley Developmental Index Scales (Corbett & Drewett, 2004). A 
conceptual framework looking at the circular relationship between nutrition and disability 
demonstrated that malnourished children, or those children at low weight for age, are more likely 
to screen positive for a developmental disability (Groce et al., 2014). Furthermore, macro- and 
micronutrition are risk factors for physical, sensory, and cognitive impairments (Groce et al., 
2014). 
Seizures 
 Infants with NAS may experience seizures (Lee, 2015, McQueen & Murphy-Oikonen, 
2016). Seizures, or a sudden surge of electrical activity in the brain (Falco-Walter et al., 2018), 
are associated with adverse developmental and intellectual effects, although there are 
inconsistent findings within the literature. Garfinkle and Shevell (2011) have identified 
predictors of adverse developmental outcomes regarding neonatal seizures. These include 




seizures, multifocal clonic seizures, tonic seizures, and myoclonic seizures. Seizures in neonates 
can affect the brain given that the associated hypoxic event leads to neurological disability and 
worse motor and cognitive outcomes (Nardou et al., 2013). Additionally, Nardou and colleagues 
(2013) identified that during a seizure, damage may occur as the cells are dividing to create new 
pathways and synapses, leading to deleterious effects. There are significant correlations between 
seizures associated with abnormal electroencephalogram (EEG) findings and impaired 
developmental outcomes beyond learning disabilities (Ronen et al., 2007). Likewise, clonic 
behavior with facial involvement significantly correlates with adverse developmental outcomes 
versus clonic seizures without facial involvement (Ronen et al., 2007). Holmes (1991), on the 
other hand, found no significant association with neonatal seizures, which equated to unknown 
protective mechanisms within the infant brain.  
 Infants born with LBW, difficulty eating and gaining weight, and seizures have shown 
significantly decreased scores on intellectual and developmental tests. These symptoms are 
found in children with NAS; therefore, the literature findings warrant further exploration. 
 In summary, a review of the literature identified inconsistent findings related to 
developmental, intellectual, behavioral, and neurophysiological outcomes. The majority of 
research does not focus on a diagnosis of NAS, but on opioid exposure during pregnancy. 
Moreover, the current literature primarily applies to children at the age of five years or younger. 
There is scant research on the health outcomes of NAS beyond early childhood. Furthermore, 
current research has minimal control for variables beyond the diagnosis of NAS that can have an 
effect on neurodevelopmental outcomes, including maternal alcohol and tobacco use, maternal 
educational level, current drug use by caregivers, medical diagnoses, diet, and prenatal control 




significant increase in NAS cases, hastens the need for an understanding of long-term health 
outcomes.  
Conclusion 
 The increased trend in diagnoses of NAS is rising at an alarming rate nationally. The 
current available research provides inconsistent findings related to neurodevelopmental health 
outcomes associated with NAS and/or exposure to opioids during pregnancy. Evidence available 
on the short-term effects of NAS raises concerns as to long-term effects. For this reason, research 
must explore the long-term developmental and intellectual health of children with a diagnosis of 
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Abstract  
Purpose: To describe the neurodevelopmental health of children with a history of neonatal 
abstinence syndrome (NAS) at 10 years of age.  
Design and Methods: This study used a retrospective, descriptive design to examine the 
demographics and neurodevelopmental health characteristics at 10 years in children with a 
history of NAS using the 1993–2011 Maternal Lifestyle Study.  
Results: Of the 234 children in this study at 10 years, the most common neurodevelopment 
health problems were abnormal cognitive development (26%), followed by language disorders 
(24%), learning disorders (23%), and abnormal behavioral development (16%). It was less 
common in our study for children to be with CP (3%), ASD (0.4%), or motor development 
abnormalities (4%).  
Conclusions: This is the first study to extend the description of NAS children beyond five years. 
From these results, approximately a quarter of children with a history of NAS have a 
developmental health problem, which is significantly higher than the general population of US 
school-age children (7%).  
Practice Implications: The study findings have practice implications for primary care nurses 
related to neurodevelopmental screening and for school nurses as they monitor the health of 










In 2014, over 32,000 newborns in the United States were born with neonatal abstinence 
syndrome (NAS), a 300% increase in the past decade (Ko, Patrick, Patel, Lind & Barfield, 2016; 
Patrick, Davis, Lehmann, & Cooper, 2015; Winkelman, Villapiano, Kozhimannil, Davis, & 
Patrick, 2018). NAS is a withdrawal syndrome experienced by newborns that includes low birth 
weight and signs of neurological excitability, gastrointestinal distress, and autonomic reactivity 
(Lee, 2015; Maguire et al., 2016; McQueen & Murphy-Oikonen, 2016). NAS occurs following 
exposure to substances in utero leading to development of dependence in the infant most 
commonly associated with opioid exposure, although it also may occur with exposure to 
methamphetamines and psychotropic medications, such as antidepressants and benzodiazepines 
(Hudak et al., 2012; Jansson et al., 2017; Jones, et al., 2010; Klinger et al., 2011; Raffaeli et al., 
2017). The physical signs of withdrawal occur when the exposure to the substance is removed 
(National Institute of Drug Abuse [NIDA], 2018).  
There is emerging evidence that NAS influences neurodevelopment among children. 
Neurodevelopmental health includes disorders affecting physical movement, learning, language, 
and behavior that alter everyday functioning (American Psychiatric Association [APA], 2013). 
Research to date indicates that NAS may impair neurodevelopment. At two years of age, a study 
found that NAS was associated with significantly more behavioral disorders, developmental 
delay, and speech disorders than those without NAS (Hall et al., 2018). Further, children with a 
history of NAS showed a significant increase in special educational services eligibility for 
speech and language impairment between the ages of three and eight (Fill et al., 2018). 
Additionally, children with a history of NAS received more speech therapy than those without 
NAS (Fill et al., 2018). Although these studies provide important initial evidence about the link 




the neurodevelopmental health of children with a history of NAS during middle childhood (i.e., 
ages 8-12) (Cooper, Garcia, Bartko, & Davis, 2005).  
The evidence to date has primarily focused on children under five years, and little is 
known about the neurodevelopmental health of children with a history of NAS in middle 
childhood. There is no information on the types of neurodevelopmental disorders or the 
prevalence among this population. Middle childhood is a critical time for development with 
important milestones, such as synapse development affecting cognitive, behavioral, and social 
development (Mah & Ford-Jones, 2012). During middle childhood, the brain grows to 
approximately 95% of adult size with increasing white matter volume and neuron growth 
(Muftuler, Davis, Buss, Head, Hasso, & Sandman, 2011). However, studies have shown an 
association between prenatal methadone and buprenorphine exposure and structural changes to 
white matter in the brain (Monnelly et al., 2018; Pujol, Soriano-Mas, Sebastian-Galles, Losilla, 
& Deus, 2006). Although we have no knowledge on how NAS may influence neurodevelopment, 
it is plausible that NAS might cause age-related changes in neurodevelopment. 
Understanding the prevalence of neurodevelopmental disorders in middle childhood is 
timely and relevant to pediatric nurses since neurodevelopment changes dramatically between 
fetal development and young adulthood (Muftuler, Davis, Buss, Head, Hasso, & Sandman, 
2011). Information about their health might provide critical information about the need for 
surveillance beyond the age of five, the maximum age for early intervention (Tennessee 
Department of Education [TDE], 2019). Understanding the child’s health may also assist school-
based nurses and counselors to ensure appropriate interventions and accommodations aimed at 
improving educational outcomes. From a policy perspective, knowledge about 




are enacted to ensure necessary medical, social, and educational support. Therefore, the purpose 
of this study was to describe the demographics, prenatal, family, and neurodevelopmental health 
characteristics of children with a history of NAS at 10 years of age. 
Methods 
Design and Data Source 
This retrospective, descriptive study used the 1993–2011 Maternal Lifestyle Study 
(MLS) dataset. The original MLS collected data on mother-infant dyads as part of a multi-site 
investigation into the effects of prenatal cocaine and opiate use on a child’s physical, social, and 
behavioral development over 16 years (Lester et al., 2016). These data include information on 
maternal drug exposure, infant/child health, and demographic characteristics. The original MLS 
had an initial enrollment between May 1993 and May 1995 at four participating centers in Rhode 
Island (Providence), Florida (Miami), Tennessee (Memphis), and Michigan (Detroit), with 
follow-up monthly for one year and yearly for 16 years.  
Enrollment and follow-up of the mother-infant dyads occurred at one of the four centers. 
Inclusion criteria for the original MLS study included exposed dyads at participating centers 
matched with those with non-exposure. Original maternal MLS exclusion criteria included: age 
under 18 years, institutionalization for retardation or emotional disorders, and evidence of 
psychosis. Original newborn MLS exclusion criteria included the following: unlikely to survive, 
multiple gestation, born at outlying facilities, greater than 43 weeks gestation, congenital 
anomaly, chromosomal anomaly, and overt TORCH infection. The present study analyzed MLS 
data collected at birth and 10 years. The Institutional Review Board at the University of 





Study Population  
The study sample was limited to children during middle childhood at 10 years with or 
without a history of in utero opioid exposure who presented with symptoms of NAS at birth 
using the MLS data. Children with missing data were excluded. After applying the inclusion and 
exclusion criteria, the final sample included 234 newborns diagnosed with NAS.  
Measures  
 The study included demographics, prenatal, family, and neurodevelopmental health 
characteristics of ten-year olds with a history of NAS. Measures were derived from the MLS 
files and prior NAS research. The variable for NAS was created using available variables of 
newborn clinical signs using the modified Finnegan NAS scoring tool (Finnegan & Kaltenbach, 
1992). A history of NAS was assigned with a score of ≥ 8 (Finnegan & Kaltenbach, 1992; 
McGuire et al., 2013). 
Demographics. Race was measured as a group of newborns with a common ancestry 
specified here as African American compared with all other races. Sex was measured as whether 
or not the child is male or female by physical examination (Lester, 1998). Birth weight in kg was 
a continuous variable of weight at birth obtained from chart review. Preterm birth was 
operationalized as a categorical variable specified as ‘yes’ for children born before 37 weeks 
gestation and ‘no’ if born at ≥ 37 weeks gestation (ACOG, 2013). 
Prenatal Characteristics. Prenatal care was measured as a continuous variable 
identifying the number of maternal visits to prenatal health care services. Prenatal tobacco 
exposure was operationalized using a continuous variable to identify the number of packs per 
day the mother smoked during pregnancy (Lester, 1998). Prenatal exposure to alcohol, cocaine, 




during this pregnancy based on the hospital interview or positive laboratory confirmation of 
exposure (Lester, 1998). A variable for polysubstance exposure was created as children with an 
exposure to two or more of the substances in utero.  
Family Characteristics. Living situation was based on with whom the child lived at 10 
years of age, either biological parent(s), extended family, foster family, adopted family, or no 
stable living situation (Lester, 1998). A binary variable was created as living situation, biological 
parent(s), or other (a combined variable for children living with extended family, foster family, 
adopted family, or no stable living situation). Household substance use was measured as the use 
of alcohol or illicit substances in the home where the child lived during the previous study year 
(Lester, 1998). Poverty was measured using the Hollingshead Four Factor Index (Hollingshead, 
1975). A binary variable was created, using the continuous Hollingshead Index, measuring the 
family’s current socioeconomic status (SES) as either low (a score between 8 and 30) or average 
(a score greater than 30) (Cirino, Chinn, Sevcik, Wolf, Lovett, & Morris 2002).  
A neighborhood safety index variable was created as a summed variable based on a 
literature review of neighborhood safety and neurodevelopment (Milam, Furr-Holden, & Leaf, 
2010; O’Campo, Wheaton, Nisenbaum, Glazier, Dunn, & Chambers, 2015; Webb et al., 2017). 
The original MLS variables of neighborhood gang activity, crimes, shootings, and rundown 
condition were summed for a value of 0–4, with a higher number indicating worse neighborhood 
safety. The clinic location was measured as the regional location of the clinic in which the dyad 
was recruited and followed during the MLS: Providence (RI), Miami (FL), Memphis (TN), or 
Detroit (MI) (Lester, 1998). Use of child services was operationalized as a dichotomous variable 
(yes/no) on the use of child services (e.g., home health care, mental health counseling, 




during the previous study year (Lester et al., 2016). Insurance was operationalized as the child’s 
current insurance status using the values Medicaid insurance versus other forms of payment (i.e., 
private insurance, HMO, or self-pay).  
 Neurodevelopmental Health. For this study, neurodevelopmental health is defined by 
medical disorders and identification of abnormal neurodevelopment. Two groups of 
neurodevelopmental health were created: neurodevelopmental disorders and abnormalities. 
Neurodevelopmental disorders included cerebral palsy (CP), autism spectrum disorder (ASD), 
attention-deficit hyperactivity disorder (ADHD), learning disorder, and language delay. CP, 
ASD, ADHD, learning disorder, and language delay were measured as dichotomous (yes/no) 
variables indicating presence of a medical diagnosis by chart review (Lester, 1998). 
The abnormal neurodevelopmental health (i.e., motor, behavioral, and cognitive) 
variables were based on an examiner’s independent assessment of the development of the child, 
completed each year during the medical data collection in the original study (Lester et al. 2016). 
Children were assessed to determine if development was normal, suspect, or abnormal in three 
categories of development (i.e., motor, behavioral, and cognitive). Licensed and trained health 
care professionals performed the developmental assessments. For the purposes of the current 
study, abnormal development was operationalized as dichotomous (yes/no) variables.  
Data Analysis  
 The aim of this study was to describe demographics and neurodevelopmental health 
characteristics of 10-year old children with a history of NAS. Standard descriptive statistics of all 
study variables were calculated including frequencies and means/standard deviations. Results are 
presented 10 years of age. All analyses were completed using SPSS v. 25 (IBM Corp., 2016), 





Descriptive statistics are displayed in Table 2.1. Most children in the sample were 
African American (74%) and male (53%). More than 40% were born preterm and the average 
birth weight was 2.6 kg. Among children in the study, prenatal substance exposure included 
alcohol (62%), cocaine (51%), marijuana (24%), opioids (11%), and combined cocaine and 
opioids (56%). The majority (80%) of children experienced prenatal polysubstance exposure of 
two or more substances. During the prenatal period, mothers of NAS children smoked an average 
of 0.28 packs per day and had an average of 8.5 prenatal visits. Most of the children were from 
Detroit (50%).  
It was common for children at 10 years to reside with their biological parent (71%), while 
less than a quarter lived in poverty. The majority (68%) of children were exposed to substance 
use in the home. Among the children in the study, 43% used child services and 69% were 
enrolled in Medicaid insurance. Average neighborhood safety index was 1.45 – suggesting a 
relatively safe neighborhood environment.  
The neurodevelopmental health disorders of children with a history of NAS at 10 years 
are shown in Figure 2.1. Relatively few children at 10 years had cerebral palsy. In our sample, 
3% of children were diagnosed with CP. Less than 1% of children were diagnosed with an 
autism spectrum disorder. The proportion of children with ADHD was 15%. Learning disorders 
were prevalent among 23% of children in the sample, while language delays were diagnosed in 
24% of children.  
Abnormal neurodevelopmental conditions were frequent among 10-year old children 
with a history of NAS (Figure 2.2). Less than 5% of children had abnormal motor development, 




Table 2.1.  
 
Characteristics of Study Sample at 10 years of Age (n=234) 
 
Variable Name Freq mean(SD) or % 
African American  174 74.4% 
Male  148 63.2% 
Female  86 36.8% 
Preterm birth  102 43.6% 
Birth weight in Kg 
 
2.58(.78) 
Number of prenatal care visits  
 
8.54(6.27) 
Prenatal tobacco exposure (p/d) 
 
0.28 (.41) 
Prenatal alcohol exposure 144 61.5% 
Prenatal cocaine exposure  119 50.9% 
Prenatal marijuana exposure  57 24.4% 
Prenatal opioid exposure  26 11.1% 
Prenatal cocaine and opioid exposure 130 55.6% 
Prenatal polysubstance exposure 186 79.5% 
Clinic 
  Detroit 117 50.0% 
Memphis 39 16.7% 
Miami 7 3.0% 
Providence 71 30.3% 
Lives with biological parent(s) 166 70.9% 
Poverty  47 20.1% 
Substance use in house  158 67.8% 
Use of child services 100 42.7% 
Neighborhood safety index 
 
1.45(.81) 
Medicaid insurance at 10 years  158 69.3% 
Note. Freq = frequency; SD= standard deviation; Preterm birth = less 
than 37 weeks gestation; p/d = packs per day; Neighborhood safety 






















Craig, 2011). Among the children in the sample, 16% had abnormal behavioral development, 
such that they present with disruptive social and emotional processes (Schlinger, 2002). The 
most common neurodevelopment issue among this population was abnormal cognitive 
development. These children had impaired mental functioning affecting thought processes and 
learning, such as remembering, reasoning, and problem solving (Sullivan, 2009). 
Discussion  
 The aim of this study was to describe the characteristics of children with a history of 
NAS at 10 years of age using data from the MLS. Few studies were identified that examined the 
characteristics of children with a history of NAS beyond the age of five. Therefore, these 
findings provide a baseline description to begin to fill this gap. The majority of children in this 
study were African American males from Detroit, MI. Most lived with a biological parent and 




ADHD, learning disorders, language delays, as well as, abnormal behavioral and cognitive 
development. Based on these findings, children with a history of NAS have a higher prevalence 
of adverse neurodevelopmental health compared to the children in the general population at this 
age (i.e., 6.9%) (Zablotsky, Black, & Blumberg, 2017).  
These findings revealed that children at 10 years with a history of NAS suffered with 
neurodevelopmental disorders. In the analysis, learning disorders, language delays, and abnormal 
cognitive development occurred in more than 20% of children with a history of NAS. The 
findings are consistent with the literature regarding NAS (Konijnenberg & Melinder, 2015; 
McGlone & Mactier, 2015); yet, contrasted with Fill and colleagues (2018) who found only 
5.3% of children with a history of NAS were eligible for educational services because of 
developmental delays between the ages of three and eight. It is possible that NAS may indirectly 
affect cognitive functioning in the developing brain of an NAS child. Although our data did not 
allow for an in-depth, biological examination of brain functioning, we do know many 
medications and drugs react in the brain similar to NAS and that these medications and drug can 
cause treatment-induced white-matter injury. White matter is the largest part of the brain and is 
made up of myelin-coated axons that are involved in cognitive functioning and language 
development (Filley, 2012; Ross, et al., 2015; Simmonds, Hallquist, Asato, & Luna, 2014; Pujol, 
Soriano-Mas, Sebastian-Galles, Losilla, & Deus, 2006). Studies have identified an association 
between prenatal methadone and buprenorphine exposure (e.g. a cause of NAS) and structural 
changes to the white matter and myelination in the newborn brain (Monnelly et al., 2018; 
Sanchez, Bigbee, Fobbs, Robinson, & Sato-Bigbee, 2008). In addition, emerging evidence 
suggest that white-matter injury may have a direct impact on frontal lobe cognitive processing 




emotional and behavioral difficulties. Thus, NAS may contribute to white-matter injury that 
affects learning and language abilities in children. Future research might explore the 
development and myelination of white matter in children with a history of NAS.  
Another interesting finding of the analysis was related to polysubstance exposure among 
NAS children at 10 years. The finding on prenatal substance exposure revealed that 80% of 
children with a history NAS had polysubstance (i.e. two or more substances) exposure (including 
tobacco), which was consistent with other studies (Hall et al., 2014; Wachman et al., 2018). One 
explanation may be that a significant number of individuals report use of one or more substances 
in addition to opioid use or heroin use (Winkelman, Chang, & Binswanger, 2018). Findings 
indicate that co-occurring substance use varies as opioid use increases (Winkelman, Chang, & 
Binswanger, 2018). Individuals with prescription opioid use disorders report co-occurring 
substance use 50% of the time and those using heroin report co-occurring substance use 88.5% 
of the time. Polysubstance exposure often occurs more frequently than single substance use, yet 
the literature does not provide an explanation. Further, polysubstance exposure (including 
methadone, buprenorphine, other opioids, amphetamines, benzodiazepines) is significantly 
associated with pharmacologically managed NAS (Isemann, Stoeckle, Taleghano, & Mueller, 
2017; Jansson et al., 2017). Research shows that individual substances (i.e., tobacco, alcohol, 
cocaine, opioids, and benzodiazepines) have differing effects on NAS (Erol, Ozcan, Celik, Bas, 
& Demirel, 2017; Hudak et al., 2012; Jones, et al., 2010; Klinger & Merlob, 2008; Raffaeli et al., 
2017). However, little is known about the interaction effects of combinations of substances on 
newborns (Lester et al., 2004; Jansson, DiPetro, Elko, Williams, Milio, & Velez, 2012). Future 
research could focus on understanding the role of polysubstance exposure in fetal development, 





 There were several limitations to note in this study. The primary limitation is that it is not 
generalizable outside of the MLS. A second limitation is the subjectivity of the abnormal 
development measures. Although the same professional (as much as possible) assessed the 
children at each visit, there was a possibility of bias related to inter-rater reliability. Another 
limitation is the lack of differentiation between substances that led to the diagnosis of NAS given 
that this variable was created based on clinical signs and not exposure. This allowed us to 
capture all newborns with clinical signs of NAS because not all substances associated with the 
diagnosis were considered in the original study (i.e., selective serotonin reuptake inhibitors, 
methamphetamines, and benzodiazepines). An additional limitation is the age of the data. The 
original MLS study enrollment occurred between 1993 and 1995, before the current opioid 
epidemic. Despite these limitations, this study used a comprehensive, longitudinal dataset of in 
utero substance exposure with detailed demographic, prenatal, and postnatal characteristics, 
along with family, medical, and social follow-up. These findings provide critical information on 
characteristics of children with a history of NAS and have implications for their care. 
Implications 
 Despite these limitations, this study has important implications for nurses. First, the 
information on disorders is critical for registered nurses in primary care and school-based 
settings. For advanced practice registered nurses (APRNs), these findings suggest that primary 
care could ensure that children with a history of NAS continue to receive neurodevelopmental 
screening up to and beyond 10. Currently, federal and state policies offer early intervention 
services to children with in utero substance exposure through the age of five (Centers for Disease 




understanding of the potential risks to neurodevelopment in middle childhood in order to develop 
policies aimed at continuing surveillance to ensure access to needed interventions.  
Second, this study has important implication for school-based nurses. There is potential 
for partnerships and coordination between primary care and school-based nurses to ensure that 
the neurodevelopmental health of these children is effectively monitored during this critical 
development phase. School-based nurses could use the BASC-3 Behavioral and Emotional 
Screening System (BESS) to monitor children with a history of NAS during middle childhood 
(Kamphaus & Reynolds, 2015). The BESS screens behavioral and emotional functioning to 
assess strengths and weaknesses providing a risk index that predicts behavioral, emotional, and 
academic problems (DiStefano, Greer, & Dowdy, 2017).  
In conclusion, this study provides an important contribution to the knowledge of the 
effect of NAS on children as they age by describing the characteristics of these children at 10 
years of age, as it is the first study to extend the description of children with a history of NAS to 
10 years. From these results, children with a history of NAS suffered significantly with 
neurodevelopmental disorders and abnormalities. In addition, the study showed that the majority 
of children with a history of NAS had prenatal polysubstance exposure with continued exposure 
to substance use by people living in their home. For these children, continued surveillance may 








ACOG. (2013). ACOG Committee opinion NO 579: definition of term pregnancy.  
 
 Obstet Gynecol, 122(5), 1139-1140. doi: 10.1097/01.AOG.0000437385.88715.4a 
 
American Psychiatric Association. (2013). Diagnostic and Statistical Man. of Ment. Disorders  
 
 (5th ed.). Arlington, VA: American Psychiatric Association.  
 
Bunikowski, R., Grimmer, I., Heiser, A., Metze, B., Schafer, A., & Obladen, M. (1998). 
Neurodevelopmental outcomes after prenatal exposure to opiates. European J. of 
Pediatrics, 157, 724-730. doi:https://doi.org/10.1007/s004310050923 
Centers for Disease Control [CDC]. (2018). What is early intervention? Retrieved from 
https://www.cdc.gov/ncbddd/actearly/parents/states.html 
Cirino, Chin, Sevcik, Wolf, Lovett, & Morris. (2002). Measuring SES: reliability and  




Cooper, C. R., Garc¡a, C. C. T., & Bartko, W. T. (Eds.). (2005). Developmental pathways 
 




Distefano, C., Greer, F., & Dowdy, E. (2017). Examining the BASC-3 BESS Parent Form- 
 




Fill, M., Miller, A., Wilkinson, R., Warren, M., Dunn, J., Schaffner, W., & Jones, T. (2018).  
 Educational disabilities among children born with neonatal abstinence  








Finnegan, L.P. & Kaltenbach K. (1992). Finnegan neonatal abstinence scoring–neonatal  
 abstinence syndrome. In: Primary Pediatric Care. 2nd ed. 1367-1378. St. Louis, MO:  
 Mosby. 
Fraser, Barnes, Biggs, & Kain. (2007). Caring, chaos and the vulnerable family: experiences  
 




Hall, E., McAllister, J., & Wexelblatt, S. (2018). Developmental disorders and medical 
complications among infants with subclinical intrauterine opioid exposures. Popul Health 
Manage, 22(1), 19-24. doi: 10.1089/pop.2018.0016 
Hall, E., Wexelblatt, S., Crowley, M., Grow, J., Jasin, L., Klebanoff, M., . . . Walsh, M. (2014).  
 
 A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence  
 
 syndrome. Pediatrics, 134(2), E527-34. doi: 10.1542/peds.2013-4036 
 
Hollingshead, A. (1975). Four Factor Index of Social Status. New Haven, CT: Yale University, 
Department of Sociology. 
Hollingsworth, A. Ruhm, C.J.,& Simon, K. (2017). Macroeconomic conditions and opioid abuse. 
 
J Health Econ, 56, 222-233. doi: 10.1016/j.jhealeco.2017.07.009 
 
Hudak, M. L., Tan, R. C., Committee On, D., Committee On, F., Newborn, & American 
Academy of, P. (2012). Neonatal drug withdrawal. Pediatrics, 129(2), e540-560. 
doi:10.1542/peds.2011-3212 




outcome in infants exposed to opiate in-utero. Early Hum Dev, 84, 29-35. doi: 
10.1016/j.earlhumdev.2007.01.013 
IBM Corp. (2016). IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp 
Isemann, Barbara T., Stoeckle, Elaina C., Taleghani, Afshin A., & Mueller, Eric W. (2017).  
 
 Early prediction tool to identify the need for pharmacotherapy in infants at risk of  
 
 neonatal abstinence syndrome. Pharmacotherapy, 37(7), 840-848. doi:  
 
 10.1080/09297049.2014.967201  
 
Kamphaus, R.W. & Reynolds, C.R. (2015). BASC-3 Behavioral and Emotional Screening  
 System (BASC-3 BESS). London: Pearson Education Inc.  
Ko, J.Y., Patrick, S.W., Tong, V.T., Patel, R., Lind, J.N., & Barfield, W.D. (2016). Incidence of 
neonatal abstinence syndrome-28 states, 1999-2013. MMWR Morb Mortal Wkly Rep, 65, 
799-802. doi: http://dx.doi.org/10.15585/mmwr.mm6531a2. 
Kolb, B., & Gibb, R. (2011). Brain plasticity and behaviour in the developing brain. J Can Acad 
Child Adoles Psychiatry, 20(4), 265-276. doi: 10.1016/B978-0-444-63327-9.00005-9. 
Konijnenberg, C., & Melinder, A. (2014). Executive function in preschool children prenatally 
exposed to methadone or buprenorphine. Child Neuropsychol,21(5), 1-16. doi: 
10.1080/09297049.2014.967201 
Jansson, L. M., Di Pietro, J. A., Elko, A., Williams, E. L., Milio, L., & Velez, M. (2012).  
  
 Pregnancies exposed to methadone, methadone and other illicit substances, and poly- 
 
 drugs without methadone: a comparison of fetal neurobehaviors and infant  
 









 Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depend, 180, 56- 
 
 61. doi: 10.1016/j.drugalcdep.2017.08.001 
 
Jarlenski, M., Barry, C., Gollust, S., Graves, A., Kennedy-Hendricks, A., & Kozhimannil, K.  
 
 (2017). Polysubstance Use Among US Women of Reproductive Age Who Use Opioids  
 




Jones, H.E., Kaltenbach, K., Heil, S.H., Stine, S.M., Coyle, M.G., Arria, A.M…..Fischer, G.  
(2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New 
Engl J Med, 364(24), 2320-31. doi: 10.1056/NEJMoa1005359.  
Klinger, G., Frankentha, D.l, Merlob, P., Diamond, G., Sirota, L., Levinson-Castiel R., . . . Inbar,  
 
 D. (2011). Long-term outcome following selective serotonin reuptake inhibitor induced  
 




Kozhimannil, K., Chantarat, T., Ecklund, A., Henning-Smith, C., & Jones, C. (n.d.). Maternal  
 
 opioid use disorder and neonatal abstinence syndrome among rural US residents,  
 
 2007-2014. J Rural Health., 35(1), 122-132. doi: 10.1111/jrh.12329 
 
Kremer, J.M., Moran, A., Walker, G., & Craig, C. (2011). Motor development. SAGE Key  
 
 Concepts series: Key Concepts in Sport Psychology. Newbury Park, CA: Sage Publishing  
 
Lee, K. (2015). Neonatal abstinence syndrome, In Bailey, R. (2015). Neonatal Abstinence  
 
Syndrome: Federal Prevention Role and Related Data. New York, NY: Novinka.  
 





Lester, B., Bada, H., Bauer, C., Shankaran, S., Whitaker, T., LaGasse, L. & Hammond, J.  
 (2016). Maternal Lifestyle Study in Four Sites in the United States, 1993-2011.  
 ICPSR34312-v9. Ann Arbor, MI: Inter-university Consortium for Political and Social  
 Research [distributor], 2016-03-31. http://doi.org/10.3886/ICPSR34312.v9 
Lind, J., Petersen, E., Lederer, P., Phillips-Bell, G., Perrine, C., Li, R., . . . Anjohrin, S. (2015).  
 
 Infant and maternal characteristics in neonatal abstinence syndrome--selected hospitals in  
 




Maguire, D.J., Taylor, S., Armstrong, K., Shaffer-Hudkins, E., Germain, A.M., Brooks,  
 
S.S….Clark, L. (2016). Long-term outcomes of infants with neonatal abstinence 
 
syndrome. Neonatal Netw, 35(3), 277-285. doi: 10.1891/0730-0832.35.5.277 
 
Mah, V. K., & Ford-Jones, E. L. (2012). Spotlight on middle childhood: Rejuvenating the 
'forgotten years'. Paediatri Child Health, 17(2), 81–83. 
McGlone, L., & Mactier, H. (2015). Infants of opioid-dependent mothers: neurodevelopment at 
six months. Early Hum Dev, 91(1), 19-21. doi:10.1016/j.earlhumdev.2014.10.006 
McQueen, K. & Murphy-Oikonen, J. (2016). Neonatal abstinence syndrome. New Engl J Med, 
375(24), 2468-79. doi: 10.1056/NEJMra1600879.  
McQueen, K., Murphy-Oikonen, A., & Desaulniers, J. (2015). Maternal substance use and  
 
 neonatal abstinence syndrome: a descriptive study. Matern Child Health, 19(8), 1756- 
 
 1765. doi: 10.1007/s10995-015-1689-y 
 
Milam, A. J., Furr-Holden, C. D. M., & Leaf, P. J. (2010). Perceived school and neighborhood  
 
 safety, neighborhood violence and academic achievement in urban school  
 





Miranda, A., & Sousa, N. (2018). Maternal hormonal milieu influence on fetal brain  
 
 development. Brain Behav, 8(2), e00920. doi:10.1002/brb3.920 
 
Monnelly, V.J., Anblagun, D., Quigley, A. Cabez, M.B., Cooper, E. Sarah, Mactier, H., Semple,  
 S. I., Bastin, M.E., & Boardman, J.P. 2018). Prenatal methadone exposure is associated  
 with altered brain development. NeuroImage: Clinical, 18, 9-14. doi: 
 10.1016/j.nicl.2017.12.033.  
National Institute of Drug Abuse [NIDA]. (2018). The Science of Drug Abuse and Addiction:  
 The Basics. Retrieved from  
https://www.drugabuse.gov/publications/media-guide/science-drug-abuse-addiction-basics.  
O' Campo, P., Wheaton, B., Nisenbaum, R., Glazier, R., Dunn, J., & Chambers, C. (2015). The  
 
 neighbourhood effects on health and well-being (NEHW) study. Health & Place, 31, 65- 
 
 74. doi: 10.1016/j.healthplace.2014.11.001 
 
Ornoy, A., Segal, J., Bar-Hamburger, R., & Greenbaum, C. (2001). Developmental outcome of  
 
 school-age children born to mothers with heroin dependency: Importance of  
 




Patel, J. Landers, K., Li, H., Mortimer, R.H., & Richards, K. Thyroid hormones and fetal  
 
 neurological development. J Endocrinol, 209(1), 1-8. doi: 10.1530/JOE-10-0444 
 
Patrick, S. W., Davis, M. M., Lehmann, C. U., & Cooper, W. O. (2015). Increasing incidence 
and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J 
Perinatol, 35(8), 650-655. doi:10.1038/jp.2015.36 





 Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural  
 




Pujol, J., Soriano-Mas, C., Sebastian-Galles, N., Losilla, J.M., & Deus, J. Myelination of  
 




Raffaeli, G., Cavallaro, G., Allegaert, K., Wildschut, E., Fumagalli, M., Agosti, M., . . . Mosca,  
 
 F. (2017). Neonatal abstinence syndrome: update on diagnostic and therapeutic  
 
 strategies. Pharmacotherapy, 37(7), 814-823. doi: 10.1002/phar.1954 
 
Ross, E. J., Graham, D. L., Money, K. M., & Stanwood, G. D. (2014). Developmental  
 consequences of fetal exposure to drugs: what we know and what we still must  
 learn. Neuropsychopharmacology, 40(1), 61–87. doi:10.1038/npp.2014.147 
Sanchez, E. S., Bigbee, J. W., Fobbs, W., Robinson, S. E., & Sato-Bigbee, C. (2008). Opioid  
 
 addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the  
 
 developing brain. Glia, 56(9), 1017–1027. doi:10.1002/glia.20675 
 
Schlinger, H. D. (2002). Concepts in behavioral development. Behavioral Development Bulletin,  
 
 11(1), 1-8. doi: 10.1037/h0100484 
 
Simmonds, Hallquist, Asato, & Luna. (2014). Developmental stages and sex differences of white  
 
 matter and behavioral development through adolescence: A longitudinal diffusion tensor  
 
 imaging (DTI) study. NeuroImage, 92, 356-368. doi: 10.1016/j.neuroimage.2013.12.044 
 
Sullivan, L. E. (2009). Cognitive development. In The SAGE glossary of the social and  
 











Thomas, S., Treffers, R., Berglas, N. F., Drabble, L., & Roberts, S. C. M. (2018). Drug use  
 
 during pregnancy policies in the United States from 1970 to 2016. Contemp Drug  
 
 Probl, 45(4), 441–459. doi: 10.1177/0091450918790790 
 
Tolia, V. N., Patrick, S. W., Bennett, M. M., Murthy, K., Sousa, J., Smith, P. B., . . . Spitzer, A.  
 
 R. (2015). Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. 
 
 N Engl J Med, 372(22), 2118-2126. doi:10.1056/NEJMsa1500439 
 
Muftuler, L.T., Davis, E.P., Buss, C., Head, K., Hasso, A.N., & Sandman, C.A. (2011). Cortical 
 
and subcortical changes in typically developing preadolescent children. Brain Res, 1399,  
 
15-24. doi: 10.1016/j.brainres.2011.05.018  
 
Villapiano, N.L.G., Winkelman, T.N.A., Kozhimannil, K.B., Davis, M.M., & Patrick, S.W.  
 
(2013). Rural and urban differences in neonatal abstinence syndrome and maternal opioid  
 




Wachman, Warden, Thomas, Thomas-Lewis, Shrestha, Nikita, . . . Schiff. (2018). Impact of  
 
 psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. Drug  
 
 Alcohol Depend, 192, 45-50. doi: 10.1016/j.drugalcdep.2018.07.024 
 
Walhovd, K.B., Westlyw, L.T., Moe, V., Slinning, K., Due-Tonnessen, P., Bjornerud, A., van  




 prenatally opiate- and polysubstance-exposed children: a diffusion tensor imaging study.  
 Am J Neuroradiol, 31(5), 894-900. doi: 10.3174/ajnr.A1957.  
Wang, Y., & Han, T. Z. (2009). Prenatal exposure to heroin in mice elicits memory 
 deficits that can be attributed to neuronal apoptosis. Neuroscience, 160(2), 330- 
338. doi:10.1016/j.neuroscience.2009.02.058 
Webb, S., Janus, M., Duku, E., Roas, R., Brownell, ,M., Forer, B…Muhajarine, N. (2017).  
 
 Neighbourhood socioeconomic status indices and early childhood development. SSM- 
 
 Population Health, 3, 48-56. doi: https://doi.org/10.1016/j.ssmph.2016.11.006 
 
Winkelman T.N., Chang V.W., & Binswanger I.A. (2018). Health, polysubstance use, and  
 
 criminal justice involvement among adults with varying levels of opioid use. JAMA Netw  
 
 Open.1(3), e180558. doi:10.1001/jamanetworkopen.2018.0558 
 
Zablotsky, B., Black, L.I., & Blumberg, S.J. (2017). Estimated prevalence of children with  
 
 diagnosed developmental disabilities in the United States, 2014-2016. NCHS Data Brief,  
 















The Effects of Neonatal Abstinence Syndrome on Neurodevelopmental Health in Children  
















































This manuscript has not been submitted for publication at this time.  
Abstract 
Introduction: To examine the effects of neonatal abstinence syndrome (NAS) on age-specific 
neurodevelopment at ages 1, 5, and 10 years. 
Method: A retrospective, longitudinal design to examine the effects of NAS on 
neurodevelopmental health outcomes, while controlling for intrapersonal, interpersonal, 
community, organizational, and public policy characteristics. A hierarchical multivariate logistic 
regression model was used to evaluate the influence of NAS on neurodevelopmental health 
outcomes. 
Results: NAS was a statistically significant predictor of adverse neurodevelopmental outcomes 
at 10 years of age. NAS was positively associated with abnormal behavioral development (OR 
2.17, p<.01). 
Discussion: Our findings identified that by the time children reach age 10, those with a history 
of NAS were at increased risk of having abnormal behavioral development. These findings 
provide a rationale for pediatric, mental health, and school-based health care providers to 















Neonatal abstinence syndrome (NAS) is an increasing problem in the United States 
(U.S.). NAS occurs following substance exposure, both legal and illicit, during pregnancy, 
leading to dependency in the infant (Hudak et al., 2012; Jones, et al., 2010; Lee, 2015). NAS is 
most commonly associated with opioid exposure, although NAS may also occur with exposure to 
methamphetamines and psychotropic medications, such as antidepressants and benzodiazepines 
(Hudak et al., 2012; Jansson et al., 2017; Jones, et al., 2010; Klinger et al., 2011; Raffaeli et al., 
2017). Over the past decade, the U.S. has experienced a 300% increase in diagnoses of NAS, 
equating to one infant born with NAS every 25 minutes (Ko, Patrick, Patel, Lind & Barfield, 
2016; Patrick, Davis, Lehmann, & Cooper, 2015; Tolia et al., 2015). In 2014 alone, nearly 
32,000 infants were diagnosed with NAS (Winkelman, Villapiano, Kozhimannil, Davis, & 
Patrick, 2018), making NAS a national health emergency.  
As newborns with NAS age and develop, there is the potential for adverse 
neurodevelopmental health outcomes, including disorders that affect physical movement, 
learning, language, and behavior emerging in childhood and affecting everyday functioning 
(American Psychiatric Association [APA], 2013). Endogenous opioid receptors are believed to 
mature throughout childhood and adolescence influencing brain development (Kolb & Gibb, 
2011; Simmonds et al., 2017). Prenatal opioid exposure may alter white matter development 
leading to structural abnormalities in the newborn brain (Monnelly et al., 2018). The evidence to 
date has focused almost exclusively on exposure to opioids in utero. From this work, we know 
that prenatal opioid exposure increases the risk for smaller overall brain volume (Sirnes et al., 
2017), reduced motor function (Bunikowski et al., 1998), and increased risk of adverse 
intellectual and developmental effects (Hunt et al., 2008). Among children at 5 years of age, 




neurodevelopmental health than those without exposure (Bunikowski et al., 1998; Hudak, et al., 
2012; Hunt et al., 2008; McGlone & Mactier, 2015). Therefore, there is compelling evidence that 
in utero opioid exposure may influence neurodevelopment in early childhood.  
Despite findings related to opioid exposure, there is still a significant gap in the 
understanding of the impact of NAS on neurodevelopment throughout childhood and 
adolescence, given few studies were identified in which this relationship was examined. 
Newborns diagnosed with NAS, born to mothers using prescribed methadone, scored 
significantly lower on the Griffith’s Developmental Quotient Scale (DQ), demonstrating 
developmental delay and abnormal visual acuity at six months (McGlone & Mactier, 2015). 
Children with a history of NAS had a higher proportion of evaluation for and diagnosis of 
educational disabilities between the ages 3 and 8 and were more likely to have classroom 
educational accommodations than children without a history of NAS (Fill, Miller, Wilkinson, 
Warren, Dunn, Schaffner, & Jones, 2018). In addition, Hall et al., showed that newborns 
diagnosed with NAS had more behavioral, emotional, and developmental diagnoses at 24 months 
of age than those who experienced in utero opioid exposure but without a diagnosis of NAS 
(Hall, McAllister, & Wexelblatt, 2018).  
Understanding the long-term effects of NAS on neurodevelopment is timely and relevant. 
Neurodevelopmental disorders have a lasting impact on children, their families, and society, as 
health care, social services, and educational support is often necessary to assist these children in 
leading successful, independent lives. The care of newborns with NAS is significantly more 
expensive than infants without NAS; in fact, in 2014 total hospital costs for NAS births covered 
by Medicaid was $462 million (Patrick, Burke, et al., 2015; O’Brien & Phillips, 2011). And we 




results in enormous costs (literally and figuratively) to families, communities, social and 
healthcare services, and society. It stands to reason, then, that with the continued increase in 
NAS, it is imperative to understand the possible neurodevelopmental effects in later childhood 
and adolescence, in order show the likely future costs. As state and federal opioid-related 
policies continue to be developed and implemented (Shearer, Erwin, Davis, Anderson, Lindley, 
2019), information on NAS and neurodevelopment may inform policy makers and key 
stakeholders. Thus, the purpose of this study was to examine these gaps and generate evidence 
about the effects of NAS on neurodevelopmental health outcomes at ages 1, 5, and 10 years. 
Theoretical Model 
The Socio-Ecological Model (SEM) was used to guide and conceptualize this study. Five 
levels of factors (i.e., intrapersonal, interpersonal, organizational, community, and public policy) 
form a reciprocal relationship that shapes behavior in the individual (McLeroy et al., 1988). The 
intrapersonal level includes factors specific to the individual, including biological make-up, 
knowledge, attitudes, and behaviors (McLeroy et al., 1988). The interpersonal level accounts for 
the effects of relationships, such as family, friends, and peer groups, on behavior. The 
organizational level details the regulations and policies that may promote or negate behaviors. 
Community factors include organizations and networks within defined boundaries or geographic 
areas (McLeroy et al., 1988). The public policy factors include local, state, and national policies 
that may have direct or indirect effects on the child. 
Conceptual Model 
Multiple factors are known to have adverse effects on neurodevelopmental health. 
Intrapersonal factors in our conceptual model included NAS and infant demographic 




volume in those affected (Sirnes et al., 2017). Additionally, low birth weight (LBW) has a direct 
association with adverse neurodevelopmental outcomes (Boulet, Schieve, & Boyle, 2011; Islam, 
2015); infants with NAS are 3 times more likely to be LBW compared with non-NAS infants 
(Fill et al., 2018). Interpersonal factors included maternal prenatal health, household 
socioeconomic status (SES), current drug use in the household, and current living situation given 
potentially negative influences on neurodevelopment (Bitsko et al., 2016; Maggi, Irwin, Siddiqi, 
& Hertzman, 2010). For example, a significant body of evidence suggests that maternal tobacco 
use is significantly associated with adverse neurodevelopment in children (Huang, Zhu, Qu, & 
Mu, 2016). Furthermore, there is strong evidence that SES has an association with 
neurodevelopment, for example as SES decreases, so does cognitive and language development 
(Webb et al., 2016).  
Organizational factors in the model included the use of child services, such as home 
health care, mental health counseling, residential treatment, or special education. Child services 
were included because of the association between neurodevelopmental disorders and referral for 
services (Shonkoff, Boyce, & McEwen, 2009). For example, early intervention services are 
associated with a minimized risk of long-term health and developmental problems (Levine & 
Schanzenbach, 2009; Islam, 2015). Community factors included region of residence and safety 
of the neighborhood, both potential influencers of adverse neurodevelopmental outcomes given 
that children living in high crime areas often exhibit signs of toxic stress, which is associated 
with adverse neurodevelopmental outcomes (O’Campo, Wheaton, Nisenbaum, Glazier, Dunn, & 
Chambers, 2015). Additionally, research indicated that living in a neighborhood that is in poor 
repair might negatively affect neurodevelopmental outcomes (Bitsko et al., 2016). Finally, public 




insurance and adverse neurodevelopmental outcomes (Levine & Schanzenbach, 2009; Bitsko et 
al., 2016).  
Methods 
Design and Sample 
 
This study used a retrospective, longitudinal, non-experimental design to examine the 
effects of NAS on neurodevelopmental health outcomes, while controlling for child, maternal, 
and other SEM characteristics as described above (McLeroy et al., 1988). Using data originally 
collected between 1993 and 2011 for the Maternal Lifestyle Study (MLS) (see below) (Lester et 
al., 2014), the unit of analysis was the child. The sampling frame included children who 
originally participated in the MLS study. The sample was limited to children ≤ 10 years of age 
with or without in utero opioid exposure to ensure inclusion of all children with potential NAS. 
Exclusion criteria included any children missing an entire time point of observation (i.e., years 1, 
5, or 10). Missing data were assessed for missing completely at random (MCAR) using Little’s 
MCAR test (McKnight et al., 2007). The chi-square test was identified as non-significant 
(p=.833), thus the missingness was MCAR. Therefore, multiple imputations were used on the 
continuous variables (i.e., neighborhood safety index) and the categorical variables (all missing 
less than 5%) were treated with case-wise deletion.  
An a priori power analysis was conducted to determine the minimum sample size 
necessary to detect the effects of NAS on neurodevelopment, if such effects exist. The 
calculation was based on widely accepted conventions of statistical power (0.80), Type II error 
rate (β=0.20), and level of significance (α=0.05). Based on prior literature (Hunt et al., 2008), a 
conservative effect size of 0.15 was used in calculating the sample size. G*Power (Faul, 




analysis with 36 regressors, a sample size of 201 children was needed. For this project, the total 
sample size was 727 children. There was sufficient power to detect variation in outcomes at the 
0.05 level of significance. 
Data Source 
The data source for this study was the 1993–2011 MLS dataset maintained and available 
through the Inter-University Consortium for Political and Social Research. The original MLS 
collected data on children, mothers, families, and communities as part of a multi-site 
investigation into the effects of maternal drug use on children’s physical and mental health over 
16 years. These data included information on prenatal drug exposure, maternal and infant 
demographics, newborn health, and longitudinal physical health, social, behavioral and 
neurodevelopmental outcomes in children. For the original MLS study, the initial enrollment 
occurred between May 1993 and May 1995 and continued until 2011 at four participating centers 
in Rhode Island (Providence), Florida (Miami), Tennessee (Memphis), and Michigan (Detroit). 
Inclusion criteria for the original MLS study included drug exposed dyads (n=658) from 
participating centers group matched with those with non-exposure (n=730), which provides a 
large cohort of children in the original study exposed to drugs in utero. Mother-infant dyads were 
enrolled at one of the four centers and longitudinal follow-up occurred monthly for the first 12 
months and yearly until children reached 16 years. The current study used data from birth, 1, 5, 
10, and 15 years. The data from 15 years were not used in analysis because of the percentage of 
missing cases. The Institutional Review Board at the University of Tennessee, Knoxville 
approved this study.  
Measures 
 
  Dependent Variables. The main outcome was neurodevelopmental health using separate 




continuous, age-related change that results in a movement outcome (Kremer, Moran, Walker, & 
Craig, 2011). Behavioral development includes the progress of social and emotional processes 
(Schlinger, 2002). Cognitive development is the expansion of thought processes and learning 
structures, such as remembering, reasoning, and problem solving (Sullivan, 2009). A member of 
the original MLS team, a certified health care provider, performed independent assessments of 
these outcomes at 1, 5, and 10 years. Each measure was the report of an examiner’s independent 
assessment of the child’s neurodevelopment (motor, behavioral, or cognitive) (Lester, 1998; 
Lester et al., 2014). The measures were dichotomized as abnormal (no/yes).  
Independent Variable. The independent variable was NAS. A measure of NAS was 
created based on the Modified Finnegan Neonatal Abstinence Syndrome (MFNAS) scoring tool, 
a widely used tool to diagnose NAS (Finnegan & Kaltenbach, 1992; McGuire, Cline, & Parnell, 
2013). The MFNAS tool uses clinical signs, which in varying combinations lead to a diagnosis 
of NAS. For this study, 18 clinical findings related to NAS (i.e. high-pitched cry, sleeping after 
eating, hyperactive moro reflex, tremors, hypertonia, excoriation, myoclonic jerks, general 
convulsions, sweating, frequent yawning, mottled skin, nasal stuffiness, sneezing, nasal flaring, 
tachypnea, excessive sucking, poor feeding, and loose stools) were identified in the MLS and 
used to generate a measure of whether an infant had NAS at birth. Four clinical findings 
(hyperthermia, regurgitation/projectile vomiting, watery stool, and tachypnea with retractions) 
were unavailable in the MLS dataset. Using the available symptom variables, an initial score was 
computed to create an NAS score. Each symptom variable was assigned the minimum score as 
identified on the MFNAS. This computed variable provided a composite score between 0 (min) 
and 35 (max). NAS was identified with a score of eight or greater, a standard clinical score used 




McGuire et al., 2013). The variable was then recoded into a dichotomous variable with 0 = less 
than 8 (no NAS) and 1 = ≥ 8 (NAS). 
Covariate Variables. A group of covariates were created for this study a priori based on 
the SEM (Lester, 1998; Hollingshead, 1975, Cirino, Chinn, Sevcik, Wolf, Lovett, & Morris 
2002; Milam, Furr-Holden, & Leaf, 2010; O’Campo, Wheaton, Nisenbaum, Glazier, Dunn, & 
Chambers, 2015; Webb et al., 2017; Lester et al., 2014). Covariate variables were used in the 
statistical models to control for factors that may influence neurodevelopmental outcomes (Polit 
& Beck, 2004). Covariate variables included, race (African American or other race), sex (male or 
female), birth weight (kg), preterm birth (< 37 weeks gestation [ACOG, 2013]), living situation 
(biological parents or non-biological parents), household substance use, socioeconomic status 
(SES), prenatal care visits, prenatal substance exposure (alcohol, opioid, cocaine, or marijuana) 
and polysubstance exposure (e.g. tobacco, alcohol, opioid, cocaine, marijuana), prenatal 
smoking, use of child services (i.e., home health care, mental health counseling, developmental 
assessment/testing, early intervention, residential treatment, or special education), neighborhood 
safety index (score 0–4 with high score less safe), location (Detroit, Providence, Memphis, 
Miami), and insurance status (Medicaid or other). 
Statistical Analysis 
Standard descriptive statistics, including means and percentages, of study variables at 
baseline and at each time point were calculated. Bivariate comparisons were made using Mann-
Whitney U tests for continuous variables and Pearson’s chi-square for categorical variables at 
birth. A hierarchical multivariate logistic regression model was used to evaluate the influence of 
NAS on each neurodevelopmental outcome, while controlling for covariates. The model fit 
indices included log likelihood and Nagelkerke R2. The assumptions of logistic regression were 




2007). Variance inflation factors (VIF) were used for confirmation. Variables identified as 
collinear were substituted to improve the model. Separate regressions were conducted for each 
age group and each measure of neurodevelopmental health. Results of the logistic regression are 
presented as odds ratio and 95% confidence intervals with p-values. All analyses were completed 
using SPSS v. 25 (IBM Corp., 2016). Statistical significance was assessed at p = 0.05. 
Results 
 Baseline child characteristics among the study sample at birth are displayed in Table 3.1. 
The sample included 727 newborns, of which 32% had a diagnosis of NAS. The majority of 
children in the study were African American (79%). Males and females were represented 
equally. Of the sample, 43% of newborns were preterm (less than 37 weeks gestation) [ACOG, 
2013] with an average birth weight of 2.63 kg. The average number of prenatal visits was 8.4. 
The mothers smoked an average of 0.28 packs of cigarettes per day. Newborns were exposed in 
utero to alcohol (58%), opioids (7.6%), cocaine (43%), combined cocaine and opioids (75%), 
and marijuana (22%). More than 75% of children had polysubstance exposure. Detroit (41%) 
was the most common clinic location, followed by Memphis (26%), Miami (17%), and 
Providence (16%). Over 80% of the study sample had Medicaid coverage. In comparing 
newborns with and without a diagnosis of NAS, newborns with NAS were more commonly male 
(63%) compared with those without NAS (48%). Most newborns with NAS were from 
Providence (62%) and Detroit (39%). The majority were on Medicaid, 76.5% and 82.6% with 







Table 3.1.  
 





NAS                  
(n=234) 
No NAS 
(n=493)   
  mean or % mean or % mean or % p-value 
Intrapersonal Factors 
    African American (N) 78.7% 74.4% 80.7% 0.05 
Female (N) 47.0% 36.8% 51.9% 0.000 
Preterm Birth  43.2% 43.6% 43% 0.88 
Birthweight in Kg 2.63 2.5 2.66 0.21 
Interpersonal Factors 
    Number of Prenatal Care Visits  8.4 8.7 8.34 0.84 
Prenatal smoking (packs/d) 0.28 0.27 0.28 0.15 
Prenatal Alcohol Exposure 58.6% 61.5% 57.2% 0.27 
Prenatal Opioid Exposure  7.6% 11.1% 5.9% 0.01 
Prenatal Cocaine and Opioid Exposure 62.0% 55.6% 65.1% 0.01 
Prenatal Cocaine Exposure  42.6% 50.4% 42.8% 0.00 
Prenatal Marijuana Exposure  21.6% 24.4% 20.3% 0.21 
Polysubstance Exposure 75.2% 79.5% 73.6% 0.07 
Community Factors 
    Clinic 
   
0.00 
Detroit 41.3% 50.0% 37.1% 
 Memphis 26.3% 16.7% 30.8% 
 Miami 16.8% 3.0% 23.3% 
 Providence 15.7% 30.3% 8.7% 
 Public Policy Factors 
    Medicaid at birth 80.6% 75.6% 82.6% 0.05 











The descriptive statistics of sample characteristics at 1 year, 5 years, and 10 years of all 
children in the study are listed in Table 3.2. At 1 year, 28% of children had a history of NAS. 
Nearly 90% of children lived with a biological parent. More than 10% of infants resided in low 
SES households. The majority of those children 1 year old (63%) were exposed to substance use 
in the home. Many infants resided in safe neighborhoods with an average neighborhood safety 
index of 1.4 and 14% of infants used a form of child services. At 5 years, 32% of the sample had 
a history of NAS. The majority of children (82%) resided with a biological parent with 16% of 
families in low SES and the average neighborhood safety score was 1.41. The majority of 
children at 5 years used child services (87%) and Medicaid (70%). At 10 years, children 
continued to mostly reside with a biological parent (77%) in a low SES household (18%). By 10 
years, children were exposed to substances use in the home (66%) and resided in neighborhoods 
with a safety index of 1.39.  More than a third of children had child services involvement and a 
majority (70%) had Medicaid insurance.   
Trends in neurodevelopmental outcomes among all children in the study at 1 year, 5 
years, and 10 years are shown in Figure 3.1. At 1 year, 21% of children had abnormal motor 
development, 8% abnormal behavioral development, and 13% abnormal cognitive development. 
At 5 years, 5% of children had abnormal motor development, 22% abnormal behavioral 
development, and 22% abnormal cognitive development. At 10 years, 3% of children had 
abnormal motor development, 18% abnormal behavioral development, and 27% abnormal 
cognitive development. Abnormal cognitive development increased steadily from 1 to 10 years, 
while abnormal motor development declined. Abnormal behavioral development trended 







Table 3.2.  
 
Descriptive Statistics of Study Sample at 1 year, 5 years, and 10 years   
 
 
1 year 5 years 10 years 		
 n=655 n=653 n=666 
	
 
mean/ % mean/ % mean/ % p-value  
NAS 27.6% 32.4% 31.9%   
Interpersonal Factors 
    Living situation (biological) 89.8% 82.4% 76.8% .008 
Low socioeconomic status 13.7% 16.3% 17.5% .59 
Substance use in house  63.1% 49.4% 65.8% .000 
Community Factors 
    Neighborhood safety index  1.41 1.41 1.39 .73 
Organizational Factors 
    Use of child services 13.8% 87.8% 37.6% .07 
Public Policy Factors 
    Medicaid insurance (birth)   70.3% 70.3% .94 
Note. a living with biological family; b safety of neighborhood ranked 0 - 4 with low score 

















Figure 3.1. Neurodevelopmental Trends among All Children in the Sample Over Time. 
 
Multivariate regression results examining the relationship between NAS and 
neurodevelopmental health outcomes at 1 year are displayed in Table 3.3. NAS was not 
associated with any of the neurodevelopmental outcomes at year 1. However, several covariates 
were related to neurodevelopmental health. Race (OR 2.0, p<.001), weight (OR .36, p<.05), 
location (Detroit [OR 7.8, p<.001], Memphis [OR 8.4, p<.001], Miami [OR 4.6 p<.05]), and 
Medicaid insurance at birth (OR .44, p<.05) were associated with abnormal motor development. 
Predictors of abnormal behavioral development included race (OR 2.8, p<.05), weight (OR .44, 
p<.01), and location (Detroit [OR 9.7, p<.01], Miami [OR 11.6, p<.01]). Abnormal cognitive 
development was influenced by weight (OR .54, p<.01), prenatal smoking (OR 1.76, p<.05), and 


















Variable Name  OR 95% CI OR 95% CI OR 95% CI 
NAS 0.83 .506-1.364 0.77 .386-1.553 1.79 1.291-2.390 
Race (African American) 2.00* 1.016-3.936 2.79* 1.174-6.630 2.12 .940-4.775 
Sex 0.70 .462-1.064 1.27 .684-2.348 0.64 .384-1.054 
Preterm birth  1.21 .676-2.149 1.12 .469-2.653 1.20 .590-2.449 
Weight (kg) .36*** .250-.522 .44** .253-.772 .54** .348-.841 
Maternal prenatal visits 0.99 .949-1.025 1.03 .980-1.080 0.98 .930-1.022 
Prenatal smoking 1.23 .762-1.992 1.55 .822-2.904 1.76* 1.021-3.020 
Prenatal exposure to alcohol  1.13 .664-1.923 0.70 .326-1.514 0.65 .469-.904 
Prenatal exposure to cocaine 1.17 .833-1.647 0.68 .273-1.677 0.53 .234-1.207 
Prenatal exposure to 
marijuana 0.94 .794-1.115 1.52 .636-3.638 0.86 .454-1.608 
Polysubstance exposure  0.65 .292-1.464 1.44 .476-4.325 1.77 1.084-2.873 
Living situation (Biological) 0.81 .382-1.733 0.39 .135-1.146 1.18 .730-1.899 
Low socioeconomic status 0.99 .472-2.077 1.41 .429-4.633 2.02 1.139-3.584 
Household substance use 1.00 .760-1.322 0.46 .193-1.078 1.65 .862-3.159 
Location   





      Detroit 7.83*** 2.433-25.227 9.74** 2.377-39.897 11.54** 5.002-26.608 
     Memphis 8.54*** 2.906-25.079 1.13 .192-6.599 3.91 1.632-9.386 
     Miami 4.56* 2.448-8.490 11.62** 2.404-56.189 3.23 .579-18.030 
Neighborhood safety index 1.03 .804-1.316 1.26 .891-1.772 0.82 .610-1.108 
Use of child services  1.21 .691-2.121 0.43 .279-.673 1.04 .494-2.195 
Medicaid insurance (birth)  .44* .219-.885 0.79 .308-2.050 0.40 .241-.647 
Note. Source: Maternal Lifestyle Study. OR= odds ratio; CI = confidence interval; Ref = 











Regression results examining the relationship between NAS and neurodevelopmental 
health outcomes at 5 years are displayed in Table 3.4. NAS was not related to any of the 
neurodevelopmental outcomes at year 5. There were several covariates related to 
neurodevelopmental health. Predictors of abnormal motor development included weight (OR .36, 
p<.01), prenatal smoking (OR 3.33, p<.01), and Medicaid insurance at 5 years (OR .21, p<.05). 
Abnormal behavioral development was associated with race (OR 2.11, p<.05), sex (2.11, 
p<.001), living situation (OR 2.05, p<.001), and Medicaid insurance at birth (OR .44, p<.05). 
Sex (OR .41, p<.001), weight (OR .50, p<.001), location (Detroit [OR 3.18, p<.05], Memphis 
[OR 9.18, p<.001]), Medicaid insurance at birth (OR .44, p<.05), and Medicaid insurance at 5 
years (OR .48, p<.05) were related to abnormal cognitive development.  
The relationship between NAS and neurodevelopmental health outcomes at 10 years are 
displayed in Table 3.5. NAS was associated with adverse neurodevelopmental outcomes at 10 
years, specifically abnormal behavioral development (OR 2.17, p<.01). Additionally, several 
covariates were related to neurodevelopmental health. Race (OR 5.67, p<0.5), prenatal exposure 
to alcohol (OR 5.2, p<.05), and use of child services (OR .02, p<.001) were related to abnormal 
motor development. Predictors of abnormal behavioral development included sex (OR .48, 
p<.01), prenatal exposure to cocaine (OR 2.42, p<.05), low SES (OR 2.49, p<.05), location 
(Detroit [OR 5.7, p<.01]), neighborhood safety index (OR 1.3, p<.001), and use of child services 
(OR .22, p<.001). Abnormal cognitive development was influenced by race (OR .4, p<.05), sex 
(OR .63, p<.05), low SES (OR 2.86, p<.01), location (Detroit [OR 5.4, p<.01], Miami [OR 4.47, 








Table 3.4.  
 









Variable OR 95% CI OR 95% CI OR 95% CI 
NAS .768 .316-1.865 .773 .491-1.218 .808 .498-1.309 
Race (African American) 1.527 .391-5.966 2.112* 1.134-3.396 .913 .436-1.910 
Sex .486 .201-1.174 .384*** .250-.590 .412*** .266-.637 
Preterm birth  .844 .250-2.852 .801 .456-1.406 1.507 .843-2.694 
Weight (kg) .360** .178-.728 .800 .566-1.131 .504*** .350-.726 
Maternal prenatal visits 1.038 .969-1.113 1.027 .990-1.065 1.025 .987-1.064 
Prenatal smoking 3.333** 1.507-7.352 1.003 .606-1.661 1.298 .772-2.182 
Prenatal exposure to alcohol  1.639 .571-4.706 1.351 .807-2.260 .969 .564-1.665 
Prenatal exposure to cocaine 1.586 .454-5.531 1.304 .668-2.543 1.250 .624-2.507 
Prenatal exposure to marijuana 1.067 .269-4.235 1.578 .861-2.889 1.333 .725-2.451 
Polysubstance exposure  1.327 .252-6.981 .712 .320-1.582 .895 .383-2.092 
Living situation (Biological) .958 .294-3.115 .486* .272-.867 .644 .352-1.178 
Low socioeconomic status .507 .181-1.418 1.751 .918-3.341 1.590 .793-3.192 
Household substance use 1.319 .549-3.169 .930 .603-1.435 .784 .500-1.229 
Location  





      Detroit .726 .166-3.172 1.740 .821-3.686 3.178* 1.154-8.753 
     Memphis .730 .150-3.550 2.223 .989-4.999 9.174*** 3.220-26.136 
     Miami .287 .041-2.019 .635 .246-1.591 1.923 .605-6.112 
Neighborhood safety index .821 .483-1.394 1.099 .868-1.391 1.085 .858-1.372 
Use of child services  .000 
 
.536 .261-1.103 .735 .386-1.400 
Medicaid insurance (birth) .859 .243-3.306 .442* .224-.875 .439* .202-.956 
Medicaid insurance (5 years) .210* .059-.748 .723 .433-1.207 .479* .269-.856 
Note. Source: Maternal Lifestyle Study. OR= odds ratio; CI = 
confidence interval; Ref = reference group.  * p<.05; ** p<.01; p<.001 




















Variable OR 95% CI OR 95% CI OR 95% CI 
NAS .853 .263-2.768 2.173** 1.295-3.645 1.228 .770-1.958 
Race (African American) 5.662* 1.402-22.876 1.032 .497-2.144 .397* .195-.808 
Sex .844 .282-2.522 .479** .302-.759 .632* .421-.948 
Preterm birth  1.181 .266-5.238 .716 .382-1.339 1.048 .600-1.829 
Weight (kg) .541 .227-1.287 1.212 .822-1.787 .768 .545-1.082 
Maternal prenatal visits .978 .888-1.078 1.025 .984-1.067 .985 .948-1.022 
Prenatal smoking .850 .308-2.350 1.230 .730-2.073 1.246 .760-2.041 
Prenatal exposure to alcohol  5.200* 1.064-25.423 1.409 .802-2.476 1.467 .865-2.488 
Prenatal exposure to cocaine .687 .143-3.309 2.425* 1.157-5.084 1.564 .810-3.022 
Prenatal exposure to marijuana .324 .061-1.713 1.250 .644-2.426 .812 .453-1.455 
Polysubstance exposure  1.639 .167-16.094 .454 .192-1.073 .767 .346-1.698 
Living situation (Biological) 1.303 .350-4.858 .698 .373-1.307 1.093 .633-1.888 
Low socioeconomic status 3.875 .343-43.808 2.486* 1.144-5.402 2.862** 1.384-5.918 
Household substance use 1.171 .367-3.735 1.586 .940-2.676 .923 .578-1.474 
Location  





      Detroit .426 .079-2.290 5.697** 2.140-15.166 5.410** 1.979-14.791 
     Memphis 1.346 .245-7.389 .646 .211-1.981 1.236 .421-3.631 
     Miami .155 .012-2.084 1.175 .390-3.536 4.469** 1.520-13.141 
Neighborhood safety index .982 .531-1.814 1.298*** 1.116-1.510 .962 .749-1.237 
Use of child services  .021*** .003-.175 .224*** .140-.358 .181*** .118-.276 
Medicaid insurance (birth) 1.611 .312-8.305 .971 .474-1.989 .518 .254-1.055 
Medicaid insurance (10 years) .114* .017-.765 .897 .505-1.595 .529* .311-.898 
Note. Source: Maternal Lifestyle Study. OR= odds ratio; CI = confidence interval; Ref = 




















 To our knowledge, this is the first study of the impact of a diagnosis of NAS on 
neurodevelopmental health over time with controls for SEM characteristics. In the present study, 
32% of children had a history of NAS. NAS was not found to be a significant predictor of 
neurodevelopment at one and 5 years, but was a significant predictor of abnormal behavioral 
development at 10 years of age.  
It was surprising that a history of NAS had no effect on neurodevelopmental health 
during the first 5 years of childhood. Our analysis indicated that NAS was not a statistically 
significant predictor of any neurodevelopment indicators at ages 1 and 5. Our findings contrast 
with those of Fill and colleagues (2018) who found that children, between the ages 3 and 8, born 
with NAS had a higher proportion of evaluation and diagnosis of educational disabilities, as well 
as a greater likelihood of educational accommodations. A possible explanation for this difference 
might be different definitions of neurodevelopment health. In this study, we defined 
neurodevelopmental health as abnormal motor, behavioral, or cognitive development as 
identified by a licensed health care practitioner per medical chart review; whereas, Fill and 
colleagues (2018) operationalized it as referral for evaluation of educational disability, eligibility 
for educational disability services, or receipt of therapy for an educational disability. Therefore, 
the specificity of measurement may have contributed to the difference in findings. 
 Our findings identified that by the time children reached age 10, children with a history 
of NAS were at increased risk of developing abnormal behavioral development. Our results align 
with Bada and colleagues’ abnormal behavioral findings. These researchers found that children 
exposed to opioids in utero scored significantly higher than those without exposure on the 




behaviors), internalizing behaviors (i.e., social withdrawal and anxiety), and significant trends 
for worsening attention scores as rated by teachers in longitudinal follow-up (Bada et al., 2007; 
Bada et al., 2011). One explanation for the abnormal behavioral development presenting later in 
life might be that NAS exposure in the developing brain may cause longitudinal changes in brain 
development (Kolb & Gibb, 2011; Monnelly et al., 2018). It is possible that NAS exposure may 
influence brain structure, specifically white brain matter (Monnelly et al., 2018). Studies have 
shown an association between prenatal methadone exposure and structural changes to the 
newborn brain’s white matter identified by MRI (Monnelly et al., 2018). White matter is 
involved in cognitive and behavioral development and is believed to mature between teenage 
years or young adulthood. Further research is needed to understand the role of NAS on brain 
structure among children.  
Alternatively, NAS may influence brain chemistry in children causing long-term 
neurodevelopment problems. Although our data did not allow for exploration to brain chemistry, 
there is a possibility that NAS might influence serotonin levels later in childhood. Studies have 
shown that intense and prolonged exposure to opioids may increase serotonin (5-HT) levels 
(Baldo, 2018). NAS is an intense and prolonged exposure to opioids. Serotonin is a 
neurotransmitter that communicates between neurons and the central nervous system, which 
affects the parts of the brain involved with depression, memory, and aggression (Davidson, 
2011). It is possible that NAS also may activate the level of serotonin. Increased serotonin is 
associated with changes during brain development manifesting through regulation of cognition, 
attention, and emotion (Brummelte, Glanaghy, Bonnin, & Oberlander, 2017). Further study of 
changes in serotonin metabolism in children with NAS is needed to understand the relationships 






This study expanded our knowledge on the effects of NAS on neurodevelopment; 
however, there are several limitations. The first limitation was variable measurement. The NAS 
variable was created using a valid and reliable measurement tool (Modified Finnegan Neonatal 
Abstinence Syndrome tool), which uses 22 identified clinical signs to assess the presence of 
NAS. In the available data, there were 18 of the 22 clinical signs identified as variables. This was 
a limitation because of the risk of underscoring infants for NAS; thus, the sample of infants with 
NAS may have been larger if all variables were available. Despite this limitation, the NAS 
variable was created using a valid tool and the presence of clinical signs that identify NAS, thus 
providing a clinically meaningful variable.  
A second limitation was the possibility of omitted variable bias. A thorough review of the 
literature identified possible confounders, allowing for inclusion in the study. An example of a 
possible omitted variable was rural versus urban living status. Although, rural/urban was not 
included in the dataset, we were able to capture location by the study site location. A third 
limitation was the age of the data. The original MLS enrolled subjects with exposure between 
1993 and 1995, which was before the current opioid epidemic. This could affect current 
outcomes, as the substances children are exposed to now differ from those >20 years ago. 
Additional prospective studies are warranted. Despite these limitations, the MLS provided 
rigorous medical and social follow-up, which allowed for control of socio-economic factors that 
influence neurodevelopment.   
Implications 
 The study findings have important practice implications. For pediatric, mental health, and 




continued neurodevelopmental evaluation of children with a history of NAS. The BASC-3 
Behavioral and Emotional Screening System (BESS) could be implemented in the clinical setting 
for children between the ages of 3 and 18 (Kamphaus & Reynolds, 2015). The BESS tool 
provides an overview of behavioral and emotional functioning through a brief interview with 
children, families, or teachers to assess both behavioral problems and strengths, including 
internalizing and externalizing behaviors. The results provide a risk index, which predicts 
behavioral, emotional, and academic problems (DiStefano, Greer, & Dowdy, 2017). This risk 
index could be used to determine the need for intervention. .  
 Additionally, the study results have policy implications. The finding that use of child 
services were inversely associated with abnormal neurodevelopmental outcomes (i.e., use of 
child services decreased risk of abnormal outcomes) supports ensuring that children with a 
history of NAS have access to support, such as developmental assessment, counseling, and early 
intervention. While not all clinicians may be familiar with regulations, pediatric health care 
providers should be informed on ways to initiate child services for these children. Efforts to 
improve access to care might include the training of NAS caseworkers to have expertise in the 
clinical and administrative management of care for children with a history of NAS. 
Finally, this NAS study on neurodevelopmental health has implications for health care 
research. Although this study examined the effects of NAS on neurodevelopmental health 
outcomes, further research should continue to examine specific neurodevelopmental disorders 
that may present in NAS children, such as internalizing (e.g. anxiety and depression) and 
externalizing behavior disorders (e.g. aggression and antisocial behavior). Additionally, future 
research should focus on understanding biological changes to provide critical insight into 




examined because of the risk of NAS on the child. Further, it is important to understand the 
etiology of changes to brain structure in NAS, as this may provide valuable insight into NAS 
management. 
In summary, the findings of this study establish a starting point for management of care 
for children affected by the opioid epidemic. By providing an understanding of potential 
outcomes, we can design future research and develop interventions aimed at reducing the 
behavioral risk for this vulnerable population. Through continued work, we have the potential to 
improve lives and promote access necessary to ensure children born with NAS have the best 
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Abstract 
Purpose: To examine the longitudinal effects of a history of NAS on learning and language 
development over the first 10 years of life. 
Design and Methods: This study used a retrospective longitudinal design.  The data were 
analyzed using generalized linear mixed models (GLMM) to examine the effect of NAS on 
learning disorders and language delay over time. 
Results: There was a significant interaction between children with a history of NAS and 
language delays over time. At the age of 1 and 5, children with a history of NAS had a 
significantly greater probability of language delay than those without NAS. At the age of 10, 
those with NAS had a lower probability of having a language delay than those without NAS. 
Learning disorders were not significantly different between NAS and no NAS groups over time.  
Conclusions: Children with a history of NAS had higher rates of language delays at the age of 1 
and 5 with lower rates at age 10.  
Practice Implications: There is a need to increase surveillance, along with referrals for 











Cases of neonatal abstinence syndrome (NAS), also known as newborn drug withdrawal, 
have increased dramatically over the past decade (Ko, Patrick, Patel, Lind & Barfield, 2016; 
Patrick, Davis, Lehmann, & Cooper, 2015). NAS occurs when a newborn exposed to substances 
prenatally develops signs of withdrawal with removal of the substance. These substances are 
most commonly opioids; however, methamphetamines, antidepressants, and benzodiazepines are 
also linked to NAS (Hudak et al., 2012; Jansson et al., 2017; Jones, et al., 2010; Klinger et al., 
2011; Raffaeli et al., 2017). NAS presents within the first five days of life with signs of poor 
feeding, tremors, uncontrollable crying, seizures, respiratory distress, and low birth weight (Lee, 
2015; McQueen & Murphy-Oikonen, 2016). In 2014, there were over 32,000 cases of NAS in 
the United States, a five-fold increase from 2004 (Winkelman, Villapiano, Kozhimannil, Davis, 
& Patrick, 2018).  
Research is emerging on the learning and language development of children with a 
history of NAS. Learning disorders lead to ongoing difficulty with reading, writing, and math  
(American Psychiatric Association [APA], 2013). Language disorders are deficits despite normal 
hearing, normal visual/nonverbal abilities, and at least low cognitive functioning (Riccio, 2013). 
Children with a history of NAS had a higher proportion of special education for speech and 
language disabilities between the ages three and eight and were more likely to speech therapy 
than children without a history of NAS (Fill, Miller, Wilkinson, Warren, Dunn, Schaffner, & 
Jones, 2018). Furthermore, Hall and colleagues (2018) showed that children with a history of 
NAS had significantly more speech disorders at 24 months of age than those with a history of in 
utero opioid exposure but without a diagnosis of NAS. These findings suggest that NAS may 




Given the potential link between NAS and language/learning development, little is 
known about the effect of NAS on these disorders. During fetal development, brain organization 
begins early in gestation, however regional brain growth continues into adulthood (Dubois, 
Dehaene-Lambertz, Kulikova, Poupon, Huppi, Hertz-Pannier, 2014). Although there are no 
studies linking NAS to abnormal brain development, studies have identified an association 
between in utero methadone and buprenorphine exposure and abnormal white matter 
development and myelination in the newborn brain (Monnelly et al., 2018; Sanchez, Bigbee, 
Fobbs, Robinson, & Sato-Bigbee, 2008). In utero methadone and buprenorphine exposure is 
directly associated with a diagnosis of NAS (Lee, 2015). Abnormal brain development might 
affect cognition and language processing, as this is the primary role of white matter (Walhovd, et 
al., 2010). Therefore, the potential changes to the brain matter and myelination due to prenatal 
exposure to opioids (e.g. a cause of NAS) might affect learning and language development in 
children with a history of NAS. 
Understanding how NAS affects learning and language development is both timely and 
relevant. Learning and language disorders can affect children throughout their lifetime and may 
increase the need for medical services and educational support. The long-term care of children 
with learning and language disorders from other causes results in high costs to families, 
communities, and society (Popova, Lange, Burd, Shield, & Rehm, 2013). With the continued 
increase in cases of NAS, there is a necessity to understand the potential effects on learning and 
language that may present in late childhood and adolescence, if for no other reason than to 
estimate future medical need and costs. Thus, the purpose of this study was to examine the 
longitudinal effects of a history of NAS on learning and language development over the first 10 





The Socio-Ecological Model (SEM) was used to conceptualize this study. The SEM 
suggests that biology and the environment (i.e., intrapersonal, interpersonal, organizational, 
community, and public policy) integrate to influence development (McLeroy et al., 1988). The 
intrapersonal level includes personal factors such as biological make-up, knowledge, and 
behaviors (McLeroy et al., 1988). The interpersonal level involves the effects of different types 
of relationships, such as family, friends, and peer groups, on behavior. Regulations and policies 
that may either promote or negate development comprise the organizational level. For example, 
organizations may influence child health, including access to child health services. Community 
factors are those within defined boundaries or geographic area that may affect development, such 
as neighborhood safety (McLeroy et al., 1988). The public policy factors include policies and 
legislation that may directly, or indirectly, affect child development. All levels of the SEM were 
used to organize covariate variables in the development of this model to ensure success in 
examining the longitudinal effects of a history of NAS on learning and language disorders.   
Methods 
Design and Sample 
This study used a retrospective, longitudinal design to examine the effects of a diagnosis 
of NAS at birth on learning and language disorders over a ten-year period. Using data originally 
collected for the Maternal Lifestyle Study (MLS) (Lester et al., 2016), the unit of analysis was 
the child. The sampling frame included children who originally participated in the MLS. To 
capture all children with a potential diagnosis of NAS in the dataset, the sample was limited to 
children 10 years of age or under with or without in utero opioid exposure. Children missing an 




G*Power (Faul, Erdfelder, Lang, and Bucher, 2007) was used to conduct an a priori 
power analysis to determine the minimum necessary sample size needed to detect the effects of 
NAS on learning and language disorders, if such effects exist. The calculation was based on 
widely accepted conventions of statistical power (0.80), Type II error rate (β=0.20), and level of 
significance (α=0.05). Based on prior literature (Hunt et al., 2008), an effect size of 0.15 was 
used in calculating the sample size. For an analysis with 36 regressors, a sample size of 201 
children was needed. For this study, the total sample size was 727 children. Power was sufficient 
to detect outcome variation at the 0.05 level of significance. 
Data Source 
This study used the MLS (1993–2011) dataset. The MLS is a restricted dataset 
maintained and available through the Inter-University Consortium for Political and Social 
Research. The original MLS, funded by the National Institutes of Health, investigated the 
longitudinal effects of maternal drug use on child health over 16 years. For the original study, 
initial enrollment occurred from May 1993 to May 1995 with longitudinal follow-up until 2011 
at four centers: Rhode Island (Providence), Florida (Miami), Tennessee (Memphis), and 
Michigan (Detroit). The original MLS inclusion criteria included drug-exposed dyads (n=658) 
from participating centers group-matched with non-exposed dyads (n=730) to provide a large 
cohort of in utero substance exposed children. These data included information on prenatal drug 
exposure, maternal and infant demographics, newborn health, and longitudinal physical health, 
social, behavioral and neurodevelopmental outcomes in the children. Mother-infant dyads were 
examined monthly for the first 12 months and yearly until children reached 16 years. The current 
study used data from birth with follow-up at 1, 5, and 10 years. The Institutional Review Board 





Outcome Variables. The outcome variables of learning disorders and language delay 
were measured at 1, 5, and 10 years of age. At 1 year, learning disorders and language delay was 
measured using the Bayley Development Scale-Mental Development Index (MDI) (Bayley, 
1993). The MDI includes items that assess memory, problem solving, early number concepts, 
generalization, and vocalization to generate a standard score, the Mental Development Index. A 
binary variable will measure the MDI using a cut off score of 85, with less than 85 being defined 
as at risk/delayed and 85 or greater being defined as normal (Gauthier, Bauer, Messinger, & 
Closius, 1999). At 5 years and 10 years, learning disorders and language delay were measured as 
a medical diagnosis per chart review conducted by original MLS investigator (Lester, 1998).  
Independent Variable. The independent variable was a diagnosis of NAS. The NAS 
variable was built using the Modified Finnegan Neonatal Abstinence Syndrome (MFNAS) 
scoring tool, a commonly used tool to diagnose NAS (Finnegan & Kaltenbach, 1992; McGuire, 
Cline, & Parnell, 2013). The MFNAS tool uses physical assessment findings to identify NAS. 
For the current study, variables within the MLS were identified that matched clinical findings of 
NAS (i.e., high-pitched cry, sleeping after eating, hyperactive moro reflex, tremors, hypertonia, 
excoriation, myoclonic jerks, general convulsions, sweating, frequent yawning, mottled skin, 
nasal stuffiness, sneezing, nasal flaring, tachypnea, excessive sucking, poor feeding, and loose 
stools). Each identified variable was assigned the minimum score per the MFNAS. Using the 
compute variable function in SPSS, an overall NAS score was created. This computed variable 
provided a score between 0 (min) and 35 (max). NAS was identified using the cutoff score of 




NAS (Finnegan & Kaltenbach, 1992; McGuire et al., 2013). The score was recoded into a 
dichotomous variable indicating a diagnosis of NAS. 
Covariate Variables. Covariates were selected a priori based on the SEM (Polit & Beck, 
2004)). Based on a review of literature (Lester, 1998; Hollingshead, 1975, Cirino, Chinn, Sevcik, 
Wolf, Lovett, & Morris 2002; Milam, Furr-Holden, & Leaf, 2010; O’Campo, Wheaton, 
Nisenbaum, Glazier, Dunn, & Chambers, 2015; Webb et al., 2017; Lester et al., 2014), 
covariates included race (African American or all other races), sex (female or male), birth weight 
(kg), preterm birth (gestational age < 37 weeks [ACOG, 2013]), living situation (biological 
parents or non-biological parents), household substance (alcohol or drug) use, low 
socioeconomic status (SES), prenatal care visits, prenatal polysubstance exposure (e.g., varying 
combinations of tobacco, alcohol, opioid, cocaine, marijuana), prenatal smoking, use of child 
services, neighborhood safety index (score 0–4 with low scores indicating neighborhoods more 
safe), location (Detroit, Providence, Memphis, Miami), and insurance status at birth (Medicaid or 
other). 
Analysis 
Data from study variables were summarized as means and standard deviations for 
continuous measures and frequencies for categorical measures. For each outcome measure, the 
data were analyzed using generalized linear mixed models (GLMM) to examine the longitudinal 
impact of a diagnosis of NAS, the interaction of NAS and time, and covariate variables on 
learning disorders and language delay. The mixed model allowed for analysis of data gathered 
from individuals with repeated observations (Tabachnick & Fiddell, 2011). GLMM includes 
fixed predictor variables, as well as random effects for repeated measurements (i.e. time) and 




variables with non-normal distributions (Heck, 2012). The assumptions of GLMM were tested: 
multicollinearity, normally distributed random effects and link function. Multicollinearity was 
identified with tolerance < .10 and variance inflation factor (VIF) < 10 (Tabachanik & Fidell, 
2013). The outcome variable was binary and assumed to have a binomial distribution, thus a 
logit link function was used (Stroup, 2013).  
For each outcome measure, models were analyzed in a sequence of increasing complexity 
(Tabachanick & Fidell, 2013). The initial model of each outcome variable included only fixed 
variables to determine the significant variables in the model (Tabachanick & Fidell, 2013). The 
second model included fixed effects for time, NAS, time * NAS interaction, and significant 
covariate variables, along with random effects for time and clinic location. Non-significant 
model terms were removed from the final model to ensure parsimony (Tabachanick & Fiddell, 
2013). Separate models were conducted for each outcome measure. The covariance structures of 
compound symmetry (CS), autoregressive covariance (AR1), and unstructured were analyzed. 
AR1 structure assumes that correlation decreases over time (IDRE, n.d.). CS assumes equal 
correlation over time (IDRE, n.d.). Akaike’s Information Criterion (AIC) was used to assess 
model fit (Tabachanik & Fidell, 2007). All analyses were completed using SPSS v. 25 (IBM 
Corp., 2016). Statistical significance was assessed at p < 0.05. 
Results 
 The descriptive data for the fixed variables of the sample are displayed in Table 4.1. The 
total sample included 727 children, in which 32% of the sample met the criteria of NAS. The 
majority of the sample were male (53%), African American (78%), and were not born preterm 
(57%). The average birth weight was 2.63 kg. Mothers had an average of 8.4 prenatal visits and 




sample were from Detroit (41%) and on Medicaid (81%). Over 70% of the sample had 
polysubstance exposure.  
The results for the GLMM examining the effects of NAS and time on learning disorders 
are displayed in Table 4.2. There was not a significantly different pattern of learning disorders 
between the NAS and no NAS groups over time. However, children with a history of NAS did 
have a significantly lower probability of learning disorders (p<.01) as they aged. 
The results for the covariate variables effect on learning disorders are displayed in Table 
4.2. Females had a lower probability (p<.001) of learning disorders. As birth weight increased by 
one unit, there was a higher probability of learning disorders (p<.001). Among children with 
exposure to alcohol in utero, there was a higher probability of learning disorders (p<.05).  
Children living with non-biological families (p<. 001) and those using child services (p<. 001) 
had a decreased probability of learning disorders. SES had an inverse relationship with learning 
disorders; as SES decreased the risk of learning disorders increased significantly (p<. 001). 
Neighborhood safety index (p<.001) was positively associated with learning disorder; as 
neighborhood safety index increased (indicating a less safe neighborhood), the risk of learning 
disorders increased. There were significant differences in learning disorders over the 3 time 
points that were likely to be related to a change in time or clinic.   
The results for the GLMM examining the effects of NAS on language delays are 
displayed in Table 4.3. There was a significant interaction between children with a history of 
NAS and language delays over time. NAS and no NAS groups had significantly different 
patterns of language delays change over at 1, 5, and 10 years. At the age of 1 and 5, children with 







 Descriptive Statistics of Study Sample (N=727) 
Variable  M  SD % 
    NAS    32.2 
African American   78.7 
Female 
Male 
  47 
53 
Birth weight (kg) 2.63 0.83  
Preterm    43.2 
Prenatal care visits  8.4 6.02  
Polysubstance exposure ()   75.2 
Prenatal smoking (pk/day) 0.28 0.43  
Location 
    Detroit 
    Memphis 
    Miami 
    Providence) 




Medicaid     80.6 




















Table 4.2.  
 
Generalized Linear Mixed Model Results of Learning Disorder (N=727) 
  Variable  Year 1 Year 5 Year 10  
Fixed Effects   
  NAS x Time interaction  1.58(21.1) .37 (.20) .22 (.12) 
NAS   -.22 (.08)** 
Time  5.58 (20.97) 4.44 (.47)*** 1.78 (.64)** 
Female sex   -.58 (.06)*** 
Birth weight (kg)   .30 (.03)*** 
Prenatal alcohol exposure    .13 (.05)* 
Living with non-biological parent(s)   -.45 (.07)*** 
Use of child services   -1.51 
(.07)*** 
Low socioeconomic status   .54 (.08)*** 
Neighborhood Safety Index   .16 (.03)*** 
Random Effect Covariance     
Variance (Time and Clinic)     .99 
(10.41)*** 
*<.05; **<.01; ***<.001; a = coefficient (standard error); b  = estimate (Z score) 
 
 
NAS. At the age of 10, those with NAS had a lower probability of having a language delay than 
those without NASAfrican American children had a lower probability (p<.001) of having 
language delays. Among children who were born preterm (p<.01) and those using child services 
(p<.001), there was a lower probability of language delay. Low SES (p<.01) was inversely 
associated with language delay; as SES decreased the probability of language delay increased. 
Neighborhood safety index (p<.001) was positively associated with language delay. Less safe the 
neighborhood the greater the risk of language delay. There were no significant differences in 
language delays over the 3 time points that were likely random from change over time or change 







Table 4.3.  
 
Generalized Linear Mixed Model Results of Language Delay (N=727) 
  
Variable Year 1 Year 5 Year 10 
Fixed Effects    
NAS x Time interaction .65 (.45)** .67 (.11)*** -.288 (.11)** 
NAS   -.31 (.08)*** 
Time -.87 (.22)** -1.82 (.54)** 1.29 (.41)** 
African American   -.18 (.07)** 
Preterm birth   -.32 (.05)*** 
Use of child services   -.72 (.06)*** 
Low socioeconomic status   .13 (.07) * 
Neighborhood Safety Index   .12 (.03)*** 
Random Effect Covariance    
Variance (Time and Clinic)   .13 (1.14) 





 In the present study, children with a history of NAS had higher rates of language delays 
at the age of 1 and 5 with lower rates at age 10. Learning disorders were not significantly 
different between NAS and no NAS groups.  
In this study, NAS was associated with language delays. Higher rates of language delays 
in children with a history of NAS were found at the ages of 1 and 5 with lower rates at the age of 
10 versus those without a history of NAS. The findings align with those of Fill et al. (2018) and 
Hall et al. (2018), who found increased language delays in children with a history of NAS 
between 24 months and 8 years of age. Higher rates of language delay in children with a history 
of NAS suggest that there may be a mechanism leading to this change. It is possible that NAS 
affects myelin development during the prenatal period (Sanchez, Bigbee, Fobbs, Robinson, & 




known that the medications and drugs that result in NAS can lead to abnormal white-matter 
development. During normal prenatal development, myelin sheaths form around axons in the 
brain white matter  (Pujol, Soriano-Mas, Sebastian-Galles, Losilla, & Deus, 2006). Myelin 
sheaths facilitate communication between neurons and are related to expressive and receptive 
language (O’Muircheartaigh, et al., 2014). Studies have shown that exposure to buprenorphine in 
utero (i.e. a known case of NAS) led to disproportionately thinner myelin sheaths during the fetal 
and early newborn period (Vestal-Laborde, Eschenroeder, Bigbee, Robinson, & Sato-Bigbee, 
2014). The thin myelin sheaths are thought to result in abnormal language development in early 
childhood (i.e. birth to eight years) (Walhovd, et al., 2010). The improvements at the age of ten 
could be associated with “late” myelination that occurs during adolescence and young adulthood 
(Vestal-Laborder et al., 2014). Further research is needed to better understand the role of NAS on 
brain development.  
Our study results revealed an association between neighborhood safety and 
neurodevelopment. This study found that neighborhood safety was positively associated with 
learning disorders and language delays over a ten-year period. This finding was consistent with 
other studies (O’Campo, Wheaton, Nisenbaum, Glazier, Dunn, & Chambers, 2015; Bitsko et al., 
2016) showing positive associations between the neighborhood safety and neurodevelopment. 
Children living in a high crime area often exhibit signs of toxic stress, which is associated with 
adverse neurodevelopmental outcomes (O’Campo et al., 2015). Toxic stress is thought to 
stimulate cortisol production through the neuroendocrine network leading to a persistent state of 
inflammation and disrupting brain development (Center for Developing Child, 2007). Further 




This study expanded our knowledge on the effect of a history of NAS on learning 
disorders and language delays, however there were limitations. The primary limitation was the 
age of the data. The original MLS enrolled subjects with exposure between 1993 and 1995, 
before the current opioid epidemic. A second limitation was variable measurement. In the current 
study, the NAS variable was created using the Modified Finnegan Neonatal Abstinence 
Syndrome tool, rather than using an ICD-9 code. The NAS variable was created using a valid 
tool and the presence of clinical signs that identify NAS, thus is provides a clinically meaningful 
variable. Despite these limitations, the MLS provided data with longitudinal medical and social 
follow-up.   
Implications  
 This study has important implications for practice. For advanced practice registered 
nurses (APRNs), these findings suggest language delays in children with a history of NAS from 
birth to five years. APRNs may monitor these children for abnormalities in language 
development and provide referrals for speech therapy, as needed. Currently, children with NAS 
can receive early intervention until the ages of 3 and 5, depending on the state (Centers for 
Disease Control [CDC], 2018; TDE, 2019), although it is not required. APRNs have an 
opportunity to assess these NAS children, who may not be using early intervention, and provide 
education to families to the impact of speech therapy on language delays.  
 This study had important policy implications. Under the Individuals with Disabilities 
Education Act [IDEA] (Lipkin & Okamoto, 2015), children through the age of 2 receive early 
intervention with the presence of developmental delay and/or disability under section C. Section 
B of IDEA (Lipkin & Okamota, 2015), provides special education for certain disabilities as 




with state and federal policy makers to ensure NAS children can access speech and language 
evaluation through the age of 10, regardless of diagnosed disability.  
 In conclusion, rates of language delay were significantly higher at the ages of one and 
five and significantly lower at the age of 10 among children with a history of NAS than those 
without NAS. This suggests that screening for language delays are warranted throughout 
childhood and adolescence for children with a history of NAS. Children with a history of NAS 
used significantly more child services at the time of the study, suggesting that despite the use of 
child services there are still risks. Pediatric nurse practitioners and public health nurses need in 
increase surveillance, and needed referrals for specialized services, for children with a history of 
NAS. The current study findings provide a preliminary understanding of potential learning and 
language delays in children with a history of NAS and provide a starting point for improvement 
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Abstract  
Opioid use during pregnancy is on the rise in the United States. Neonatal abstinence syndrome 
(NAS), also known as newborn drug withdrawal, is a public health epidemic. Between 1999 and 
2011, Tennessee experienced a 11-fold increase in NAS hospitalizations, from 0.7 to 8.5 per 
1000 live births. Soaring increases in the number of newborns with NAS nationwide have caught 
the attention of many federal and state lawmakers, especially given the unknown burdens 
associated with medical and social services needed by those affected over time. Tennessee 
opioid-related regulations and laws enacted between 2000 to 2018 were systematically reviewed 
and analyzed to identify each law’s purpose, effects on families and individuals, pros and cons in 
terms of social, practical, and legal factors, and implications for nursing practice. Our findings 
were that Tennessee’s laws are intended to decrease the number of opioids prescribed, ensure 
access to continued prenatal care and substance abuse management for mothers with substance 
use disorders, and reduce the ease of obtaining opioids. We also found that Tennessee lawmakers 
have enacted laws and regulations aimed at decreasing the abuse of opioids, but not reducing the 
incidence of NAS. As new laws are considered, it is critical that health care providers and 
lawmakers work together to ensure that the developed and enacted laws strike a balance between 
safely managing the care of both pregnant women and their newborns without producing 
negative outcomes.   






Opioid use during pregnancy is on the rise in the United States (Patrick et al., 2015). 
Neonatal abstinence syndrome (NAS), also known as newborn drug withdrawal, is a public 
health epidemic (Bauer & Li, 2013). Between 1999 and 2011, Tennessee experienced an 11-fold 
increase in NAS hospitalizations, from 0.7 to 8.5 per 1000 live births (Bauer & Li, 2013). In 
2013, nearly 28,000 newborns in the United States were born with NAS (Ko et al., 2016; Patrick, 
Davis, et al., 2015). Soaring increases in the number of newborns with NAS nationwide have 
caught the attention of many federal and state lawmakers, especially given the unknown burdens 
associated with medical and social services needed over time. Tennessee has enacted several 
opioid-related laws and regulations between 2000 and 2018, yet there have been limited 
systematic reviews of these policies, specifically related to how these policies affect NAS, which 
is at epidemic levels in the state. The research question we sought to answer is: To what extent 
do Tennessee’s opioid-related laws and regulations impact newborns with NAS and their 
families. After an overview of the epidemiological factors pertaining to opioid use and NAS in 
TN, this article has three main sections: (a) an overview of the Tennessee opioid-related laws and 
regulations enacted since 2000, (b) an analysis of the impact on NAS, and (c) implications for 
nurses, including why and how nurses can influence the legislative outcomes and inform 
policymakers of actual and potential consequences of laws, both positive and negative, and 
whether intended or unintended.  
Background of Opioid Use in Tennessee 
In 1999, 342 residents of Tennessee, age 15 and older, died from prescription medication 
overdose and 5% of Tennessee residents in publicly funded addiction treatment were receiving 
treatment for pain management addiction (Tennessee Department of Mental Health and 




rates of opioid use among all states, reaching over 1,000 overdose deaths annually (Center for 
Disease Control [CDC], 2014). Prescription opioids surpassed alcohol as the primary abused 
substance (Substance Abuse and Mental Health Services Administration [SAMHSA], 2012). 
More Tennesseans died in 2014 from opioid overdoses than motor vehicle accidents 
(TDMHSAS, 2014). Furthermore, between 2012 and 2014, 4% of Tennessee residents who were 
18-25 years of age, roughly 207,000 individuals, used opioids without a prescription (Tennessee 
Department of Mental Health and Substance Abuse Services [TDMHSAS], 2016). Additionally, 
24,000 high school students reported using opioids for non-medical use in their lifetime between 
2012 and 2014 alone (TDMHSAS, 2016). Despite the reduction in the number of opioid 
prescriptions dispensed in Tennessee between 2013 and 2017 (Centers for Disease Control 
[CDC], 2018), there is an increase in overall opioid deaths in Tennessee associated with the use 
of heroin and synthetic opioids, such as fentanyl (Melton & Pellegrin, 2018). Between 2015 and 
2016, Tennessee saw a 14% increase in overdose deaths with a 58% increase in deaths associated 
with heroin and fentanyl (Melton & Pellegrin, 2018).  
Overview of NAS 
The significant rise in opioid abuse in Tennessee has led to an increase in the number of 
newborns with NAS. NAS leads to low birth weight, neurological excitability, gastrointestinal 
distress, and autonomic reactivity manifesting as signs including inconsolable and high-pitched 
crying, increased muscle tone, difficulty eating, poor weight gain, and seizures beginning within 
five days of life (Lee, 2015; Maguire et al., 2016; McQueen & Murphy-Oikonen, 2016). The 
research on the long-term effect of NAS on development is still emerging throughout childhood 
and adolescence, however findings indicate ad adverse effect on neurodevelopment. For 




Quotient Scale by demonstrating developmental delay and abnormal vision at the age of six 
months (McGlone & Mactier, 2015). Children, ages 3 and 8, born with NAS were more likely to 
have a diagnosis of educational disabilities and educational accommodations in the classroom 
than those without NAS (Fill, Miller, Wilkinson, Warren, Dunn, Schaffner, & Jones, 2018). In 
addition, a study of children with NAS found more behavioral, emotional, and developmental 
diagnoses than those opioid exposed with no NAS (Hall, McAllister, & Wexelblatt, 2018). 
Therefore, ongoing research indicates a positive association between NAS and abnormal 
development.  
States in the southeastern part of the country, including Tennessee, Kentucky, 
Mississippi, and Alabama, have NAS rates nearly three times higher than the national average 
(Patrick et al., 2015). Some counties in Tennessee, especially in northeastern Tennessee, have 
rates of NAS of 60 per 1,000 live births, roughly 10 times the national average (Brown, Doshi, 
Pauly, & Talbert, 2016; Miller, McDonald, & Warren, 2018). The type of opioid associated with 
cases of NAS in Tennessee varied by region (Erwin, Meschke, Ehrlich, & Lindley, 2017). 
Overall, NAS in Tennessee is associated with maternal prescription opioid misuse (Miller & 
Warren, 2014; Erwin et al., 2017). However, NAS specific to Eastern Tennessee is associated 
with maternal illicit use of opioids, including heroin and diverted-prescription opioids. Hence, 
pregnant women in Eastern Tennessee were less likely to obtain opioids as part of a prescribed 
treatment than mothers in other parts of Tennessee.  
In 2013, Tennessee Department of Health (TDH) made NAS a mandatory reportable 
condition and established the Tennessee Surveillance System for Neonatal Abstinence 
Syndrome, which requires hospitals and treating physicians to report all cases of NAS to TDH, 




2015). Instating mandatory reporting of NAS enhanced understanding of the incidence and 
prevalence of NAS in the state (Warren et al., 2015). By understanding the incidence of NAS, 
the state of Tennessee was able to compare NAS births with other factors, such as total births, to 
have a better overall understanding of the effect of NAS on state resources. One example of a 
trend the state was able to monitor was total births in contrast to NAS births. Between 2013 and 
2014, there was a 1% decrease in total births in Tennessee, while cases of NAS increased almost 
13% (Tennessee Division of Health Care Finance & Administration [TNDHCFA], 2016). In 
2014, the incidence of NAS among newborns with Medicaid was 21.3 per 1000 live births, up 
from 5.3 per 1000 live births in 2008. The total health care expenditures during the first year of 
life for all live births in Tennessee covered by Medicaid in 2014 totaled over $384 million for 
45,824 births; over $51 million of that total was for the 1,063 babies born with NAS 
(TNDHCFA, 2016). In other words, the Medicaid expenditures for a newborn with NAS was 10 
times higher than the cost for a normal weight newborn, and 1.3 times higher than the average 
cost for low birth weight newborns (TNDFFCA, 2016). Additionally, in 2014, the average length 
of hospital stay for a Tennessee newborn with NAS was 24.1 days compared to a 3.3-day 
average for all live births (TNDHFCA, 2016). Therefore, the epidemic of opioid abuse and 
misuse in Tennessee, along with the increasing number of newborns experiencing NAS, 
prompted state policymakers to address and control the problem.  
What is Known and Unknown About Laws Affecting NAS 
 Laws that have an impact on NAS in the United States vary in purpose and severity of 
litigation. Between 1974 and 2016, the number of states that developed policies focused on drug 
use during pregnancy increased from 1 to 43 (Thomas, Treffers, Berglas, Drabble, & Roberts, 




most frequent (Thomas et al., 2018). In 2015, three states (Tennessee, Alabama, and South 
Carolina) considered substance abuse during pregnancy a crime (Krans & Patrick, 2016). 
Tennessee was the only state to have a law specifying that drug use in pregnancy is a crime, 
although it has since been rescinded due to lack of legislative support for the law (Krans & 
Patrick, 2016). Alabama and South Carolina interpret child endangerment laws to include drug-
using pregnant women and new mothers (Krans & Patrick, 2016).  
 Eighteen states define drug use during pregnancy as child abuse: Alabama, Arkansas, 
Colorado, Florida, Illinois, Indiana, Iowa, Louisiana, Minnesota, Nevada, Oklahoma, Rhode 
Island, South Carolina, South Dakota, Tennessee, Texas, Virginia, and Wisconsin (Krans & 
Patrick, 2016). Three (Minnesota, South Dakota, and Wisconsin) states view drug use during 
pregnancy as grounds for involuntary civil commitment to a treatment program. For example, 
Wisconsin provides the fetus a court-appointed lawyer and there is a risk of the mother losing 
custody after delivery (Krans & Patrick, 2016). Additionally, 15 states (i.e., Alaska, Arizona, 
Illinois, Iowa, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Montana, North 
Dakota, Oklahoma, Rhode Island, Utah, and Virginia) require health care workers to report 
women who they suspect are using drugs during pregnancy.  
 Although some states are enacting laws aimed at penalizing pregnant women for the use 
of opioids during pregnancy, the legal ramifications of such laws often deter women from 
seeking prenatal health care and create an adversarial relationship between the women and their 
health care clinicians (Kremer & Arora, 2015). Additionally, evidence does not indicate 
improvement in maternal health outcomes with incarceration. To the contrary, obstetrical 
emergencies are common among incarcerated women because of acute opioid withdrawal 




increasing the requirement for obtaining opioids to assisting women to receive needed support; 
thus, critical analysis of individual state laws is vital to understand the effects of the laws on 
newborns with NAS in order to best assist the legislature with evidence to guide policy 
development. 
Methods 
 We used a systematic approach for this policy analysis (Teitelbaum & Wilensky, 2017). 
Searches of the state of Tennessee website (TN.gov) and PUBMED identified state legislative 
laws and regulations related to opioid use, misuse, and abuse using the key words “health policy” 
AND “opioids” OR “neonatal abstinence syndrome.” The search was limited to legislative 
opioid laws and regulations in the state of Tennessee between the years 1999 and 2018 and 
excluded federal opioid policies, thus, identifying seven Tennessee laws and regulations. We 
analyzed the opioid laws to identify the purpose of the enacted law, effects of the law on 
newborns and families, and the pros and cons of the policy using social, practical, and legal 
factors.  
Conceptual Framework 
In this policy analysis, we systematically analyzed Tennessee’s opioid-related laws and 
regulations to understand the impact on the NAS epidemic using the process outlined by 
Teitelbaum and Wilensky (2017). Table 5.1 includes the constructs of the process and includes 
identification of the policy problem, provision of evidence to understand the significance of the 
problem, and identification of policies and key factors related to the problem. Key factors refer 
to the social, practical, and legal aspects of the opioid-related policies (Teitelbaum & Wilensky, 
2017). An understanding of the key factors is necessary to make informed decisions regarding 




Table 5.1.  
Policy Analysis Constructs 
Construct  Definition 
Problem Statement Defining the policy problem being analyzed 
Background Provision of information and evidence needed to understand the problem 
Landscape Provision of the overall context of the problem, including identification of 
key stakeholders and their positions and examination of key factors (i.e. 
social, practical, and legal) related to the problem. 
Options Identification and analysis of policies with inclusion of pros and cons 
Note. Adaptation of the analysis process outlined by Teitelbaum and Wilensky (2017) 
 
The social factors pertain to the fairness of the policies for those affected by the problem. 
The practical factors explore to what extent the policies solve the problem. The legal factors 
concern the legal implications of the policies, such as legal restrictions, legal uncertainty, and 
potential for future litigation with policy implementation (Teitelbaum & Wilensky, 2017). The 
key stakeholders are those people who have a significant interest in the outcomes of these 
policies, such as newborns, mothers, nurses and other health care professionals, state legislature, 
taxpayers, and social services. The policy analysis concludes with a discussion of the potential 
impact of these policies on key stakeholders and future research (Teitelbaum & Wilensky, 2017). 
Thus, examining Tennessee opioid-related laws and regulations provides critical insight into the 
effects of these laws, particularly the affected neonates and families in Tennessee.  
Results 
Overview of Laws and Regulations 
 There were seven opioid-related laws and regulations enacted in Tennessee between 2000 




Chapter 820) are no longer in effect. Opioid-related laws in Tennessee addressed varying aspects 
of opioid use including ensuring pain management per the patient’s wishes, monitoring how 
frequently patients are obtaining opioids, and managing the licensure of directors of private pain 
management clinics.  
The Intractable Pain Treatment Act (IPTA) of 2001, known as the pain patient’s bill of 
rights, identified the need to use a team of medical professionals to address pain and the 
associated issues, including psychological, social, and vocational concerns (Public Chapter 327 
[PC327], 2001). The IPTA was one of the first Tennessee opioid-related laws and set the tone for 
the expectation of the management of pain, per the patient’s wishes. The IPTA provided patients 
with the option to request or reject any or all methods of relieving chronic pain and to choose 
opioid medications to relieve intractable pain, as they saw fit (PC327, 2001). Intractable pain is 
incurable, extreme pain that has failed treatment with methods such as non-steroidal anti-
inflammatory drugs, physical therapy, and mild opioid medications (Tennant & Hermann, 2000). 
The IPTA allowed physicians to refuse to prescribe opioids for intractable pain; however, the 
prescribing physicians were to notify the patient that there are specific physicians who primarily 
treat chronic pain (i.e., pain management clinics). The IPTA required physicians to notify 
patients of alternative means of obtaining opioids if the physicians, themselves, refused to 
prescribe the medication (PC327, 2001). The bill was repealed in April 2015 due to concerns of 
significant increase in opioid use, the increase in private pain management clinics, and rising 
incidence of NAS (McMillan, 2015).   
The Controlled Substance Monitoring Act of 2002, Public Chapter 840, created the 





Table 5.2.  
Overview of Tennessee Opioid-Related Laws from 2000-2018 







2001 - 2015 63-6-1104 Ensures pain patient's bill of rights 
Controlled Substance 
Monitoring Act  
2002 53-10-301 Monitors patient's receiving controlled substances 
and dispensers prescribing controlled substances 
Public Chapter 820 2014 - 2016 39-13-107  Allows for criminal prosecution of mothers for 
the use of an illegal narcotic during pregnancy if 
the child was born dependent to the narcotic  
Tennessee Prescription 
Safety Act  
2012 53-10-301 Requires dispensers and dispenser agents to 
report to the Controlled Substances Monitoring 
Database 
Tennessee Safe Harbor 
Act 
2013 33-10-104 Ensures pregnant women access to publically 
funded drug treatment centers and prohibits 
termination of parental rights if mother's seek and 
continue treatment by the 20th week of 
pregnancy 
Addison Sharp Act 2013 63-1-401 
Ensures that current regulations are enforced, 
creates protocols for managing the controlled 
substances used to treat chronic pain, and 
establishes restrictions on the quantities and 
combinations of controlled substances that may 
be prescribed  
NAS Mandatory 
Reporting 
2013 N/A Requires mandatory reporting of cases of NAS 
through a real-time, statewide surveillance system 









federal and state laws, and education of health care professionals to monitor patients acquiring 
controlled substances (Public Chapter 840 [PC840], 2002). All health care professionals legally 
authorized to dispense controlled substances are required to submit the required information to 
the Controlled Substance Monitoring Database (Public Chapter 1002 [PC1002], 2016). In 2016, 
amendments to this law required dispensers to upload a list of the day’s controlled substance 
prescriptions to the database every day (Public Chapter 1011 [PC1011], 2014). 
Public Chapter 820 (PC 820) of the Public Acts of 2014, also known as Tennessee’s fetal 
assault law, allowed Tennessee District Attorneys to prosecute women who used illegal narcotics 
during pregnancy, if the newborn was born dependent to the opioids (Public Chapter 820 
[PC820], 2014). PC820 allowed for charges of assault against mothers and, if convicted, they 
could serve time in jail (Salter, Ridley, & Cummings, 2015). The intent of PC 820 was to address 
illicit drug use during pregnancy and allow pregnant women to receive help through treatment 
programs and drug courts, thus reducing the numbers of newborns with NAS. Due to concern 
regarding potential unintended effects of PC 820, a provision was added to the statute, allowing 
lawmakers to assess the impact of the law on maternal and newborn outcomes (Salter et al., 
2015) and then let it sunset (meaning lapse) in two years without further legislative action. 
Lawmakers did not have support to extend PC 820 and it ended on July 1, 2016.   
The Tennessee Prescription Safety Act of 2012 (amended in 2016) aimed to curb the 
opioid epidemic by requiring all dispensers (pharmacists) and dispenser agents (health care 
practitioners with the authority to dispense controlled substances) to report to the Controlled 
Substance Monitoring Database (Public Chapter 880 [PC880], 2012). The amendment in 2016, 
Public Chapter 1002, made the law permanent (PC1002, 2016). It also included the requirement 




prescriptions, or new pharmacy dispensing, and, at a minimum, annually for all patients. The 
Prescription Safety Act of 2016 increased the required frequency of reporting to the Controlled 
Substance Monitoring Database from every seven days to daily (PC1002, 2016). Additionally, 
the 2016 amendment clarified that an “unusually high pattern of prescribing, distributing, or 
dispensing” that is not otherwise explainable, will trigger a referral for investigation by the 
appropriate health care board (PC1002, 2016). A goal of the revised law was to increase patient 
quality of care by providing real time information to practitioners in an effort to determine the 
need for counseling and/or intervention for substance abuse (PC1002, 2016). 
The Tennessee Safe Harbor Act of 2013 was an effort to reduce the number of pregnant 
women who misuse controlled substances with the intent to reduce the number of newborns with 
NAS (Public Chapter 398 [PC398], 2013). Under PC 398, pregnant women referred for 
substance abuse treatment receive priority treatment from publicly funded drug treatment centers 
(PC398, 2013). The Safe Harbor Act ensures that women seeking treatment from a center 
offering management for substance use disorders do not get treatment refused. The bill ensures 
that the Tennessee Department of Mental Health and Substance Abuse Services provide family-
oriented drug abuse and dependence treatment. Obstetrical providers encourage pregnant women 
who use opioids to obtain substance abuse treatment. Assuming the pregnant woman seeks 
treatment by the 20th week of pregnancy, maintains treatment compliance throughout pregnancy, 
and receives prenatal care, then the Department of Children’s Services will be prohibited from 
petitioning for termination of the mother’s parental rights on the sole account of the use of 
prescription drugs for non-medicinal purposes (PC398, 2013).     
The Addison Sharp Prescription Regulatory Act of 2013, Public Chapter 430 (PC 430), 




substances used to treat chronic pain, and establishes restrictions on the quantities and 
combinations of controlled substances that may be prescribed (Public Chapter 430 [PC430], 
2013). Additionally, PC 430 requires mandatory training on prescriptive protocols with the 
purpose of regulating pain medication dispensing within pain management clinics, including a 
limit on dispensing of medication to a 30-day supply at one time. PC 430 provides regulation of 
pain management clinics or any privately owned facility that provides pain management services 
for opioids, benzodiazepines, barbiturates, or carisoprodol. The regulations require clinic 
licensure and mandate that patients have current and valid government identification, be referred 
to the clinic by a licensed physician, submit to drug screening, and have current diagnostic 
testing for the basis of the prescription (PC430, 2013). In addition, pain management clinics 
must have a medical director who is a physician with an unrestricted and unencumbered medical 
license, with a presence of no less than 50% of weekly hours.   
In 2013, the TDH made NAS reporting mandatory through a real-time, statewide 
surveillance system known as the Tennessee Surveillance System for Neonatal Abstinence 
Syndrome (Warren, et al., 2015). Previous data collection occurred through a delayed technique 
of reviewing hospital discharge documentation. Using an online reporting platform, facilities 
report newborns with a diagnosis of NAS based on clinical symptoms, as well as history of 
exposure, supporting evidence (such as positive urine or meconium drug screens) and source of 
substances causing the NAS, if known. The online reporting allows for rapid, secure collection 
of data. Thus, providing the opportunity for Tennessee to gather information on the number of 
newborns affected by the disorder, thereby informing efforts to improve outcomes through 





Between 2000 and 2017, Tennessee, located in the epicenter of the US opioid epidemic, 
enacted laws that directly and indirectly affected newborns with NAS. The purpose of this policy 
analysis was to understand these state-level, opioid-related laws and their effects on the statewide 
NAS epidemic in terms of social, practical, and legal factors (Teitelbaum & Wilensky, 2017). 
The laws had weak, moderate, or high effects on NAS (see Table 5.3). A weak assessment 
indicates a policy that negatively affects the outcomes for each factor. Moderate demonstrates a 
fair, positive effect on outcomes. A high assessment indicates a positive or favorable effect on 
outcomes associated with NAS. 
Social Factors 
We reviewed the laws to determine their effect on the societal problem, as well as their 
fairness to the people and groups affected. The escalation of opioid use following the IPTA led 
to the need for enactment of policies aimed at controlling and improving the opioid epidemic. 
Tennessee saw a ten-fold increase in the diagnosis of NAS after enactment of the IPTA (Miller, 
McDonald, & Warren, 2018). Cases of NAS have increased in Tennessee every year since 1999 
(Miller et al., 2018).  
The Tennessee Surveillance System for Neonatal Abstinence Syndrome provides an 
opportunity to understand the demographics of newborns affected by NAS, thus rationalizing the 
provision of necessary social services for the population. Accurately counting the number of 
Tennessee newborns affected by NAS and knowing the percentages of newborns diagnosed with 








 Analysis of Effect of Opioid Laws on NAS 
  Social Perspective           Practical Perspective  Legal Perspective  
Intractable Pain Treatment 
Act 
weak weak weak 
Controlled Substance 
Monitoring Act  
moderate moderate high 
Public Charter 820 weak weak weak 
Tennessee Prescription 
Safety Act  
moderate moderate high 
Tennessee Safe Harbor Act high high high 
Addison Sharp Act weak moderate moderate 
NAS Mandatory Reporting high high high 
Note: Author's assessment of effect of Tennessee’s laws on NAS. A weak assessment indicates a negative 
effect on outcomes. Moderate indicates a fair, positive effect. A high assessment indicates a positive or 
favorable effect 
 
with an opportunity to identify state policies needed for their care, development, and optimal 
health outcomes. The United States reached $12 billion in hospital charges for NAS in 2012 
(Patrick et al., 2015). In Tennessee, Medicaid covered over $53 million in health care for babies 
with NAS in 2015 (Tennessee Division of Health Care Finance & Administration [TDHCFA], 
(2017). By decreasing access to and use of opioids by women during pregnancy, there is a 
potential to decrease the number of cases of NAS, thus decreasing overall federal and state 
taxpayer burden. 
The Safe Harbor Act empowers mothers to obtain the necessary support for substance use 
disorders (SUD) and dependency during pregnancy by removing the fear of loss of parental 
rights in the process. Thus, the Safe Harbor Act potentially increases the number of pregnant 




newborns with NAS. Conversely, PC 820 may have led mothers not to pursue the standard care 
for substance use disorders during pregnancy given the fear of prosecution (Erwin, et al., 2017). 
This fear of prosecution, in turn, may have increased the number of cases of NAS. Between May 
2013 and May 2014, there was a 1.9% increase in the number of pregnant women entering 
treatment for SUD; from July 2014 and January 2015, there was a 2% drop (Tennessee 
Department of Mental Health and Substance Abuse Services [TDMHSAS], 2016). These trends 
coincided with the enactment of both the Safe Harbor Act of 2013 and PC820. Thus, Tennessee 
policies may have had indirect positive effects (increase in SUD treatment with the Safe Harbor 
Act) and negative societal effects (decreased SUD treatment with PC 820) on NAS. 
Practical Factors 
We assessed the laws and regulations for their practical health care effect on NAS. The 
Controlled Substance Monitoring Act of 2002 can provide information, as needed, to determine 
if the mother of a child with NAS was prescribed opioids during pregnancy, as well as the 
associated morphine milligram equivalents. Understanding the associated morphine milligram 
equivalents provides the potential for development of scoring tools using the relationship 
between maternal morphine milligram equivalents and diagnosis of NAS (Tennessee Department 
of Health [TDH], 2017). Additionally, women in Tennessee receive relief of concern regarding 
social services intervention because of the Safe Harbor Act. Women can now safely visit 
obstetrical services without fear of their newborn being placed in an alternative home (PC398, 
2013), thus potentially increasing the number of women receiving prenatal care and substance 
use therapy throughout pregnancy. The data provided through the mandatory reporting of NAS 
can identify regions of Tennessee most affected by NAS and assist in developing location-




prescriptive practices (Warren et al., 2013). The Addison Sharp Act provides oversight to 
communities in which pain management clinics exist. This Act has the potential to affect the 
number of newborns diagnosed with NAS by reducing the ease of obtaining large quantities of 
opioid pain medications. 
The Tennessee Prescription Safety Act may decrease the number of newborns affected 
with NAS by decreasing the number of pregnant women who use opioids, along with the dosage 
of opioids taken by the mother. Of the more than 2,000 cases of NAS in 2013 and 2014, 588 
newborns (around 30% of cases) were born to mothers in the Controlled Substance Monitoring 
Database (TDH, 2017). In 2013, the Tennessee Surveillance System for Neonatal Abstinence 
Syndrome reported that 27.3% of NAS cases in Tennessee were attributed to supervised pain 
management, psychiatric, or neurologic therapies, 46.7% were associated with medical 
replacement therapy, and an additional 26% were associated with illegal substance use (Miller & 
Warren, 2014). These numbers support the findings of the Controlled Substance Monitoring 
Database. Although Tennessee has not seen a decrease in the number of NAS diagnoses since the 
introduction of the Tennessee Prescription Safety Act in 2012, there have been improvements in 
other areas. Specifically, there has been a 32% decrease in morphine milligram equivalents 
dispensed between 2012 and 2017 and a 14% decrease in opioid prescriptions between 2105 and 
2017 (Tennessee Department of Health [TDH], 2018). Additionally, the rate of increase of new 
cases of NAS in Tennessee slowed to 2% between 2016 and 2017, although further analysis is 
necessary to establish whether there is a direct association to the Controlled Substance 
Monitoring Database. 
 Not all opioid-related policies have a positive impact on patient outcomes in Tennessee. 




(PC327, 2001). By allowing patients to decide if they needed opioids, the IPTA provided a 
loophole for patients to bypass the opinion of their primary health care provider, allowing 
patients to continue to receive opioids (McMillan, 2015). Additionally, PC 820 may have 
deterred women from seeking prenatal care for fear of prosecution, thus impeding access to care 
for pregnant drug-using women (Burke, 2016; Krans & Patrick, 2016; Erwin et al., 2017). 
Furthermore, the change in processes for obtaining opioids made necessary by these laws could 
lead to women obtaining opioids through illegal channels, thus negating the potential decrease in 
opioid usage. Thus, opioid-related policies in Tennessee may have both positive and negative 
effects on the incidence and prevalence of NAS. 
Legal Factors 
We reviewed Tennessee laws and regulations to understand the legal implications. The 
use of the Controlled Substance Monitoring Database has resulted in a significant decrease in 
morphine milligram equivalents (Goodin, 2014). Additionally, Tennessee has seen a 63% 
decrease in potential “doctor and pharmacy shopping” between the years 2011 and 2016 (TDH, 
2017). The Tennessee Prescription Safety Act of 2016 may affect the incidence of mothers 
accessing prescription opioids, as the law requires health care practitioners to check the database 
before writing or dispensing a new prescription, or once every 12 months (PC1002, 2016). 
There were negative legal impacts of the opioid-related laws as well. The enforcement of 
the IPTA led to a proliferation of pain management clinics in the state (McMillan, 2015). The 
increase in the number of these private pain management clinics eventually required legislation 
aimed at managing the types and amounts of controlled substances prescribed, leading to passage 
of the Addison Sharp Act (PC430, 2013). In PC 820, women receiving medically managed care 




risk to the newborns, thus fewer women may have sought assistance during pregnancy leading to 
an increase in newborns with NAS (Erwin et al., 2017). Additionally, there is a potential impact 
on the burden placed on the judicial system through the increased use of drug courts and lawsuits 
stemming from the enacted laws. Conversely, the Safe Harbor Act may lead to decreased 
prosecution of mothers receiving necessary care, increasing the number of pregnant women 
receiving drug treatment. Therefore, legal ramifications of the opioid-related policies in 
Tennessee regarding NAS demonstrate both positive and negative effects with a positive decline 
in morphine milligram equivalents and a negative effect on prosecution of pregnant women.   
Limitations  
We identified limitations of this policy analysis. First, because of a lack of mandatory 
reporting before 2013, it is difficult to understand fully the impact of state legislation on 
diagnoses of NAS: how much of the increase is real versus how much is artifact because of 
mandatory reporting? Before 2013, chart review at discharge identified cases of NAS, which has 
the potential for loss of cases. Second, the standard of care for maternal treatment for opioid 
addiction does not prevent NAS. The current standard of treatment is the use of medication-
assisted therapy (MAT) using either buprenorphine or methadone (ACOG, 2017). Despite the 
use of MAT to reduce the licit or illicit use of opioids, both buprenorphine and methadone may 
lead to NAS (Hudak & Tan, 2012; Jones et al., 2010; Lee, 2015). Thus, the Safe Haven Law may 
not result in a change in outcomes until the standard of care is changed. Third, the complicated 
but continual increase in cases of NAS makes it extremely difficult to conclude any direct cause 
and effect of the opioid-related laws on cases of NAS. Fourth, without data collection relevant to 





Another limitation of this study is the generalizability. This policy analysis is specific to 
the state of Tennessee, thus the findings are not generalizable to other states. However, 
Tennessee is one of the states with the most cases of NAS and Tennessee was the first to enact 
laws directly aimed at prosecuting mothers for the use of opioids during pregnancy. Thus, the 
results may not be generalizable, but they may provide vital information to policymakers in other 
states seeking ways to improve the incidence of NAS. 
Implications for Nursing Practice, Policy, and Research 
Our policy analysis has implications for nursing practice and advocacy of NAS-related 
policies. Given the profound effects of the opioid epidemic on newborns, it is important for 
maternal child, OB, and pediatric nurses, along with midwives and women’s health nurse 
practitioners to be aware of the opioid-related legislation affecting newborns and their families. 
Collaboration between primary care providers and obstetricians can help encourage safe 
management of pregnancies affected by SUD and nurses may provide necessary education to 
prospective parents, as well as pregnant women, on the potential risk of in utero opioid use on 
the newborn. The unique position of public health nurses allows for the development of 
educational programs to ensure that the community understands the effect of opioids on 
newborns, as well as to inform the public of regulatory changes related to the care of these 
newborns. Nurses need to be involved in critical conversations regarding healthcare policy 
through involvement with local, state, and federal organizations ensuring a collective voice 
regarding the care of newborns with NAS. Nurses must be involved with state and federal 
nursing organizations, such as the Tennessee Nurses Association (TNA) and American Nurses 
Association (ANA), respectively. State and federal nursing organizations provide the opportunity 




policy making. Thus, nurses have a significant role in ensuring legislation that meets the needs of 
children with NAS. 
 Our policy analysis has implications for nursing research. Through the analysis of current 
laws and regulations, our findings demonstrated the importance of examination of Tennessee 
laws in well-designed research studies. For example, research could examine the influence of 
Public Chapter 820 on NAS births in Tennessee. Providing more evidence about the impact of 
laws on NAS better informs policymakers; thus, improving the health of newborns affected by 
the opioid epidemic. Research is underway regarding the safe detoxification of mothers during 
pregnancy and resulting decrease in negative outcomes in the neonate, including reduced NAS 
(Nelson, 2017). Findings from Bell’s (2016) maternal detoxification study could affect the 
American Colleges of Obstetricians and Gynecologists (ACOG) regulations and change the 
standard of care for detoxification of pregnant mothers, leading to the need for the development 
of appropriate detoxification procedures (Bell, Towers, Hennessey, Heitzman, Smith, & Chattin, 
2016). Current ACOG lists MAT as the standard of care for managing opioid use during 
pregnancy (American Colleges of Obstetricians and Gynecologists [ACOG], 2017). A change in 
the ACOG recommendations would create the necessity to determine if the Safe Harbor Act of 
2013 has a direct effect on NAS. Future research could explore how morphine milligram 
equivalents affect diagnosis of NAS, thus, potentially providing new prescribing practices of 
health care professionals.  
 In summary, our policy analysis provided an overview of Tennessee’s laws and 
regulations pertaining to opioid use. This analysis provided critical information regarding how 
opioid laws might affect NAS. Tennessee provides a unique look at governmental intervention to 




regulations and laws. Future policy analyses could focus on comparing the policies of two or 
more states. Specifically, comparing the policies of states with strict opioid laws against those 
with minimal opioid laws may provide a well-rounded look at how policy intervention affects 
newborn outcomes. As new laws are considered, it is critical that health care providers and 
lawmakers work together to ensure that the developed and enacted laws strike a balance between 
safely managing the care of both pregnant women and their newborns without producing 
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 This dissertation consists on five manuscripts exploring the effect of NAS on the  
neurodevelopmental health over a ten-year period.  Research to date focused primarily on 
children under the age of five with prenatal exposure to opioids, rather than a diagnosis of NAS. 
This work extended that knowledge by analyzing data on children who presented, during the 
newborn period, with the clinical signs and symptoms of NAS to examine the effect of NAS on 
neurodevelopmental outcomes through the age of ten. These studies identified that at the age of 
ten children with a history of NAS experienced learning disorders, language delays, abnormal 
behavioral development, and abnormal cognitive development. At the age of ten, NAS 
significantly predicted abnormal behavioral development. Further, over the first ten years of life 
children with a history of NAS had a significantly different risk of language delay than those 
without NAS.  
The first manuscript, a systemic review of the literature, was completed to describe the 
current state of the science related to the effect of NAS on neurodevelopmental health to identify 
gaps in the literature and to discuss the possible association between the symptoms of NAS and 
neurodevelopmental disorders. The current research shows inconsistent findings on 
neurodevelopmental outcomes in children with a history of NAS, as most research focuses on 
outcomes associated with exposure to opioids in utero rather than a diagnosis of NAS. This 
review revealed a need for further research to explore the long-term developmental health in 
children with a history of NAS.  
 The second manuscript described the demographics and neurodevelopmental health 
characteristics of children with a history of NAS at 10 years. Data on children (n=234) from year 
10 of the MLS (Lester, 1998) were analyzed. Children in this study included children with and 




was the first known study describing these children at 10 years of age. Children with a history of 
NAS were found to have learning disorders (23%), language delays (24%), abnormal behavioral 
development (16%), and abnormal cognitive development (26%). Few children in the study were 
found to have cerebral palsy, autism spectrum disorder, or abnormal motor development. The 
study revealed that a quarter of children with a history of NAS had abnormal neurodevelopment. 
This study supports further research aimed at understanding the effect of a history of NAS on 
neurodevelopment over time.  
 The third manuscript examined the effect of a history of NAS at 1, 5, and 10 years of age. 
Ten years of data on children included in the MLS (Lester, 1998) from children with a history of 
NAS (n=727) were analyzed. The socio-ecological model (SEM) was the theoretical perspective 
for this study (McLeroy et al., 1988). NAS was not found to be a significant predictor of 
neurodevelopment at 1 and 5 years, but was a significant predictor of abnormal behavioral 
development at 10 years of age (p<.01). Additional significant predictors of abnormal behavioral 
development based on the SEM were identified, including African American race, sex, prenatal 
exposure to cocaine, living with the biological family, low socioeconomic status, use of child 
services, and neighborhood safety. This study revealed a need for further research examining the 
role of NAS in development of brain structure and serotonin metabolism.  
 The fourth manuscript examined the longitudinal effect of NAS on learning disorders and 
language delays in children through the age of 10. Data from the MLS (Lester, 1998) was 
examined using a generalized linear mixed model to examine the longitudinal effect of NAS on 
learning and language. The socio-ecological model (SEM) was the theoretical perspective that 
guided this study (McLeroy et al., 1988). There was a significant change in learning disorders 




those without a history of NAS. At years 5 and 10, there was a significant change although the 
change was not significantly different between groups. Further, there was a difference between 
children with a history of NAS and language delays, such that the pattern of language delay 
changed at 1, 5, and 10 years was significantly different for the NAS and no NAS groups. At the 
age of 1 and 5, children with a history of NAS had a significantly risk of language delay than 
those without NAS. At the age of 10, those with NAS had a lower risk of language delay than 
those without NAS. This study expanded our knowledge on the effect of a history of NAS on 
learning disorders and language delays suggesting the use of continued screening for language 
delays throughout childhood and adolescence for children with a history of NAS.  
 The fifth manuscript was a policy analysis that analyzed the Tennessee opioid-related 
policies enacted between 2000 to 2018 were systematically reviewed and analyzed to identify 
each law’s purpose, effect on families and individuals, social, practical, and legal factors, and 
implications for nurses. This policy analysis used a systematic approach outlined by Teitelbaum 
and Wilensky to identify the problem, identify the policies and factors related to the problem, 
and discussed the impact of the policies (2017). Seven opioid-related laws and regulations were 
reviewed for social, practical, and legal context. While Tennessee has enacted policies aimed at 
reducing the opioid epidemic, few have been enacted that result in reduction in NAS. Currently, 
the standard management of pregnant women with substance use disorders involves medication-
assisted therapy (MAT) using methadone or buprenorphine (ACOG, 2017). The substances used 
in MAT are known to result in cases of NAS (Hudak & Tan, 2012; Jones et al., 2010; Lee, 
2015). Thus, until prenatal substance use disorder management changes, it will be difficult to 
significantly reduce the number of newborns with NAS. The cumulative results of these studies 




Implications for Practice 
There are important implications for clinical practice derived from this work. First, this 
work identifies opportunities for advanced practice registered nurses (APRNs). Pediatric and 
family APRNs are in a position to ensure that children with a history of NAS receive continued 
monitoring and screening for abnormal neurodevelopment, specifically abnormal behavioral 
development and language delay. Since the majority of research to date focuses on children up to 
the age of five, this work suggests that children through middle childhood could benefit from 
evaluation. This work also has implications for school-based nurses, as they are in the position to 
work closely with teachers and administrators to ensure that children with a history of NAS 
receive the necessary surveillance for behavioral, cognitive, and language disorders.  
Implications for Research  
There are many implications for research from this work. The exploration of the effect of 
NAS on long-term neurodevelopment has provided ample areas for follow-up. This work 
focused on a group of children identified as having a history of NAS by newborn clinical signs 
and symptoms to provide preliminary findings on this population of children. To continue to 
build upon the knowledge, future research is recommended. This work used a group of children 
born between 1993 and 1995, and future research should focus on children with NAS born 
during the current opioid epidemic, as well including children with exposure to 
methamphetamines, selective-serotonin reuptake inhibitors, and benzodiazepines. First, it is 
important to continue the study on the developmental effect of NAS on brain structures during 
prenatal and postnatal life. Additionally, it is possible that NAS affects serotonin metabolism 
during fetal development and this has important research implications both in the newborn 




in utero affects NAS. This research topic can be extended to examine the effect of polysubstance 
exposure on fetal brain development, as well as the longitudinal neurodevelopmental outcomes.  
Implications for Policy  
 This dissertation work has important policy implications. The findings from this work 
demonstrated that children who use child services (e.g., home health care, mental health 
counseling, developmental assessment/testing, early intervention, residential treatment, or special 
education) are at a decreased risk for abnormal behavioral development. The findings support the 
development and enactment of policies aimed at ensuring children with a history of NAS have 
access to needed monitoring and evaluation of abnormal neurodevelopment though middle 
childhood. Clinicians may not have current knowledge of the available services, thus the creation 
of NAS caseworkers specially-trained in the management of these children could improve access 
to care. Further, without a diagnosis of disability children may not receive access to early 
intervention and special education services. Thus, nurses could work with policy makers to 
ensure they have an understanding of the effect of NAS on long-term neurodevelopment to 
develop policies aimed at improving the health of these children.  
 In conclusion, this study has extended to knowledge of neurodevelopmental outcomes in 
children with a history of NAS. To date, research primarily focused on children through the age 
of five with prenatal opioid exposure. This study identified that through the age of 10, these 
children present with learning disorders, language delays, and abnormal behavioral and cognitive 
development. Continued monitoring and evaluation may provide an opportunity for 
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